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ABSTRACT
5-Aminolevulinate synthase (ALAS; EC 2.3.1.37) is a pyridoxal 5’phosphate (PLP)-dependent enzyme that catalyzes the first committed step of
heme biosynthesis in animals, the condensation of glycine and succinyl-CoA
yielding 5-aminolevuliante (ALA), CoA, and CO2. Murine erythroid-specific ALAS
(mALAS2) variants that cause high levels of PPIX accumulation provide a new
means of targeted, and potentially enhanced, photosensitization. Transfection of
HeLa cells with expression plasmids for mALAS2 variants, specifically for those
with mutated mitochondrial presequences and a mutation in the active site loop,
caused significant cellular accumulation of PPIX, particularly in the membrane.
Light treatment of HeLa cells expressing mALAS2 variants revealed that
mALAS2 expression results in an increase in cell death in comparison to
aminolevulinic acid (ALA) treatment producing a similar amount of PPIX.
Generation of PPIX is a crucial component in the widely used photodynamic
therapies (PDT) of cancer and other dysplasias. The delivery of stable and highly
active mALAS2 variants has the potential to expand and improve upon current
PDT regimes.
Mutations in the C-terminus of human ALAS2 (hALAS2) can increase
hALAS2 activity and are associated with X-linked erythropoietic protoporphyria
(XLEPP), a disease phenotypically characterized by elevated levels or PPIX and
xii

zinc protoporphyrin in erythroblasts. This is apparently due to enhanced cellular
hALAS2 activity, but the biochemical relationship between these C-terminal
mutations and increased hALAS2 activity is not well understood. HALAS2 and
three XLEPP variants were studied both in vitro to compare kinetic and structural
parameters and ex vivo in HeLa and K562 cells. Two XLEPP variants, delAGTG,
and Q548X, exhibited higher catalytic rates and affinity for succinyl-CoA than
wild-type hALAS2, had increased transition temperatures, and caused porphyrin
accumulation in HeLa and K562 cells. Another XLEPP mutation, delAT, had an
increased transition temperature and caused porphyrin accumulation in
mammalian cells, but exhibited a reduced catalytic rate at 37°C in comparison to
wild-type hALAS2. The XLEPP variants, unlike wild-type hALAS2, were more
structurally responsive upon binding of succinyl-CoA, and adopted distinct
features in tertiary and PLP cofactor-binding site. These results imply that the Cterminus of hALAS2 is important for regulating its structural integrity, which
affects kinetic activity and stability.
XLEPP has only recently been identified as a blood disorder, and thus
there are no specific treatments. One potential treatment involves the use of the
antibiotic isonicotinic acid hydrazide (isoniazid, INH), commonly used to treat
tuberculosis. INH can cause sideroblastic anemia as a side-effect and has
traditionally been thought to do so by limiting PLP availability to hALAS2 via
direct inhibition of pyridoxal kinase, and reacting with pyridoxal to form pyridoxal
isonicotinoyl hydrazone. We postulated that in addition to PLP-dependent
inhibition of hALAS2, INH directly acts on hALAS2. Using FACS and confocal
xiii

microscopy, we show here that INH reduces protoporphyrin IX accumulation in
HeLa cells expressing either wild-type human hALAS2 or XLEPP variants. In
addition, PLP and pyridoxamine 5’-phosphate (PMP) restored cellular hALAS2
activity in the presence of INH. Kinetic analyses with purified hALAS2
demonstrated non-competitive or uncompetitive inhibition with an apparent Ki of
1.5 µM. Circular dichroism studies revealed that INH triggers structural changes
in hALAS2 that interfere with the association of hALAS2 with its PLP cofactor.
These studies demonstrate that hALAS2 can be directly inhibited by INH,
provide insight into the mechanism of inhibition, and support the prospective use
of INH in treating patients with XLEPP and potentially other cutaneous
porphyrias.

xiv

CHAPTER 1: INTRODUCTION
Biosynthesis of 5-aminolevulinate and heme
Heme plays a central role in nearly all living organisms due to its vital
functions in biological processes such as, respiration, gas sensing (1,2) and
oxygen metabolism and transport (3). Heme also functions as an essential
cofactor for cytochromes P450, catalases, and peroxidases (4). Heme
biosynthesis begins with the condensation of succinyl-CoA and glycine,
catalyzed by 5-aminolevulinate synthase (ALAS), to form 5-aminolevulinic acid
(ALA) (5). The reaction proceeds as follows:

Glycine + Succinyl-CoA  CoA + CO2 + ALA.

In the final reactions of the pathway, protoporphyrinogen IX is oxidized to
protoporphyrin IX (PPIX), into which ferrous iron (Fe2+) is inserted to form heme,
a reaction catalyzed by ferrochelatase (Figure 1.1) (6,7).
One molecule of heme is made from eight molecules of ALA, the common
precursor to all naturally occurring tetrapyrroles, in either eight or nine enzymatic
steps, depending on the organism (8). In nature, ALA is synthesized by two
distinct routes. Mammals, fungi, and α-proteobacteria synthesize ALA from
glycine and succinyl-CoA, via the C4 pathway, while in plants, archaea, and most
1

bacteria, ALA is synthesized from glutamyl-tRNA via the C5 pathway (Figure
1.2). In all organisms except one, the photosynthetic phytoflagellate Euglena
gracilis (9-13), production of ALA for tetrapyrrole synthesis is carried out by only
one of these two pathways.
The first evidence for the utilization of glycine as one of the initial
precursors of heme was presented in 1945 by David Shemin when he infamously
synthesized and then ingested 66g of 32%

15

[N] glycine in addition to his usual

diet (14). He observed that the isotopic nitrogen of glycine was incorporated in
his blood’s heme, and he concluded that the nitrogen atoms of heme are derived
from the NH3 group of glycine (14). The initial proposal that glycine represents
one of the early precursors of heme was confirmed and expanded to animal
subjects, demonstrating that among various amino acids, glycine was directly
utilized as the predominant source for the nitrogen atoms of heme (15). It was
evident that the nitrogen atoms of heme were derived from glycine, but there
remained the question of to what extent glycine was utilized as a source for the
heme carbon atoms. Altman et al. (16) demonstrated that only the α-carbon of
glycine was incorporated into heme, whereas its carboxyl carbon was not (17).
Thus, the carboxyl group of glycine had to be lost during some stage of heme
synthesis.
Since the α-carbon of glycine accounted for only 8 of the 32 carbon atoms
of heme (18), the search for the potential substrate(s) other than glycine
intensified. At this time, several groups suggested the involvement of an
intermediate from the TCA cycle as a possible precursor of heme, with α2

ketoglutarate as the most plausible candidate (18,19). However, Shemin and
Wittenberg (20) proposed that the precursor used for heme formation was a fourcarbon, asymmetric compound, and therefore they rejected any direct
involvement of α-ketoglutarate or succinate in heme biosynthesis. Their
conclusion for the involvement of a four-carbon asymmetric compound was
based on the observed isotopic distribution patterns of the individual carbon
atoms in heme synthesized in the presence of labeled acetate. Briefly, heme was
synthesized by incubating avian erythrocytes with acetate whose carboxyl group
was labeled with
labeled with

14

C and by incubating with acetate whose methyl group was

14

C (20). Following its synthesis and isolation, heme was degraded

into individual chemical components in order to identify the positions of the
isotopic carbon atoms. The observed isotopic distribution patterns of the
individual carbons strongly argued against direct involvement of α-ketoglutarate
or succinate in heme biosynthesis; instead, the isotopic distribution patterns
suggested a four-carbon, asymmetric compound serving as the precursor for all
the non-glycine-derived carbon atoms of heme (20). It was proposed that the
four-carbon, asymmetric compound was most likely a succinyl-coenzyme
complex derived from the TCA cycle (20), and the validity of this proposal was
corroborated several years later with the observation that the synthesis of ALA in
bacterial and avian extracts exhibited dependence on succinyl-CoA (21,22).

3

Figure 1.1. The heme biosynthetic pathway. Numbers designate individual enzymecatalyzed steps of heme biosynthesis and are as follows: 1) ALA synthase, 2) ALA
dehydratase, 3) uroporphyrinogen synthase, 4) uroporphyrinogen-III cosynthase, 5)
uroporphyrinogen
decarboxylase,
6)
coproporphyrinogen
oxidase,
7)
protoporphyrinogen oxidase, and 8) ferrochelatase. Abbreviations are as follows: ALA,
5-aminolevulinate synthase; PBG, porphobilinogen; HMB, pre-uroporphyrinogen;
UROIII, uroporphyrinogen III; COPROIII, coproporphyrinogen III; PPGIX,
protoporphyrinogen IX; PPIX, protoporphyrin IX.

4

Figure 1.2. Biosynthesis of ALA via the C4 and C5 pathways. ALA is the common
committed precursor to tetrapyrroles and is biosynthesized by two routes. Plants and
most bacteria synthesize ALA from glutamyl-tRNAGlu by reduction of glutamate to
glutamate-1-semialdehyde. This is then converted to ALA by glutamate-1-semialdehyde
aminotransferase. Non-plant eukaryotes and the α-subclass of purple bacteria
synthesize ALA by the C4 pathway, which requires the respiratory intermediate succinylCoA. Euglena gracilis, an extraordinary unicellular organism with properties of both
plants and animals, has the capacity to synthesize ALA by both pathways.

5-Aminolevulinate Synthase
There are two isoforms of ALAS expressed by two separate genes in
animals (23). Human ALAS1, the housekeeping gene, is located on chromosome
3p21 (24) and the first complete nucleotide sequence of ALAS1 was obtained
using chick embryo liver (25), which represented the first complete nucleotide
sequence of ALAS to be cloned from any source. After this initial report of the
5

full-length cDNA clone, Elliott and colleagues (26) proceeded to isolate the
chicken ALAS gene and its putative control regions. The chicken ALAS gene
spans 6.9 kb of DNA and alignment with the chick embryo cDNA sequence (25)
shows that it is divided into 10 exons ranging from 156-280 bp, split by 9 introns
of more variable length (26). The 10 exons contain 2103 nucleotides, which
encode an ALAS precursor protein of 635 amino acids.
ALAS2, the erythroid-specific gene, is located on the X-chromosome
(23,24). The mouse ALAS2 gene consists of 11 exons and 10 introns, spanning
approximately 24 kb (27). The first exon consists of 37 base pairs of non-coding
sequence and is separated from the body of the gene by a 6 kb intron.
Consistent with the similarity observed between the mouse ALAS2 cDNA
sequence and the chicken ALAS1 sequence (25,28), the location of the
intron/exon boundaries 3' of exon 3 are virtually identical in chicken ALAS1 (26).
A notable difference is the absence of a distant and non-coding first exon in the
chicken. Also, the chicken ALAS1 introns are generally more modest in size, as
the chicken gene spans only 6.9 kb.
Like mouse ALAS2, human ALAS2 also consists of 10 protein-coding
exons and a 5’-untranslated exon (29) that contains sequence coding for an ironresponsive element important for the regulation of mRNA translation (30,31). The
human gene structure bears remarkable similarity to the mouse ALAS2 (27). An
examination of the immediate promoter of the human ALAS2 gene by Cox et al.
(30) revealed several interesting putative cis-acting motifs. Unlike that of the
mouse erythroid ALAS gene, the human promoter contains a consensus TATA
6

box at position -27 and a consensus CCAAT box at position -87. Cox et al. (30)
also identified a possible GATA-1 binding site located at position -100. At position
-40 there is a perfect consensus for NF-E2, another erythroid-specific factor
found in the promoter of the erythroid porphobilinogen deaminase (PBGD) gene
(32,33) and upstream of β-globin (34-36).

Regulation of ALAS2 Transcription
ALAS1 and ALAS2 each have evolved distinct transcriptional regulatory
processes, likely correlated with the stringent regulation necessary for the large
heme requirement during erythropoiesis that is not required in non-erythroid cells
(37). Hence, during erythropoiesis, transcription of all genes for ALAS2 and the
other heme pathway enzymes and globin (38) are clearly up-regulated (39).
Transcription of human ALAS2 is regulated by erythroid-specific transcription
factors that act at the promoter and intronic enhancer sites (37,40), as well as
downstream of the gene in the 3’-flanking region (41). In 1989, Schoenhaut and
Curtis (27) published the structure of the mouse ALAS2 gene and identified the
DNAse I hypersensitivity sites. Since many enhancer-like sequences associated
with other erythroid-specific sequences are marked by DNAse I hypersensitivity,
in 1998 Surinya et al. (31,40) set out to determine whether the intronic
sequences corresponding to DNAse I-hypersensitivity in the mouse ALAS2 gene
play a role in human ALAS2 transcriptional regulation. The significance of introns
1, 3, and 8 on ALAS2 expression were assessed by analysis of the effects of
intron deletions, revealing that intron 3 is marginally inhibitory and introns 1 and 8
7

are stimulatory. Intron 8 conferred the strongest stimulation of promoter activity in
K562 and MEL cells, and was found to be orientation-dependent. Specifically a
239 bp region located within intron 8, which is highly conserved in the human,
mouse, and dog ALAS2 genes, was identified as the region conferring enhancer
activity. In K562 cells, a 25-fold level of stimulation was observed when the
enhancer was located upstream of the promoter and oriented in the same
direction as the promoter, while only a 4-fold increase was observed when the
enhancer was in the reverse direction. In this region, two CACCC box binding
sites and four GATA-1 binding sites were identified, and functional contributions
were assessed through site-directed mutagenesis experiments and gel shift
assays to determine binding of individual transcription factors. Mutational
analysis demonstrated that the two CACCC boxes and one of the GATA motifs
were functional. The CACCC boxes each bind Sp1, but not erythroid Krüppel-like
factor (EKLF) or basic Krüppel-like factor (BKLF), and the GATA motif binds
GATA-1 in vitro (40).
In 2000, Kramer et al. (42) further examined the role of GATA-1 in the
transcriptional regulation of murine ALAS2. They investigated the function of the
5’-flanking region of the murine ALAS2 gene in erythroid and non-erythroid cells,
as well as in erythroid cells chemically induced to undergo differentiation.
Transient transfections of mammalian cell lines with different sections of the
murine ALAS2 promoter indicated that the first 700 bp of the murine promoter
were required to give maximal expression. Specifically, it was found that the first
700 bp of the mouse ALAS2 promoter are essential for maximal expression in
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murine erythroleukemia (MEL) cells and human myelogenous leukemia (K562)
cells, although these regions stimulated similar expression in the human cervical
carcinoma

(HeLa)

cells

and

mouse

embryonic

fibroblasts (NIH

3T3).

Furthermore, in the mouse ALAS2 5’-flanking region, there are two critical GATA1 binding sites within the first 300 bp; however additional upstream cis-acting
elements are also necessary for maximal transient transcriptional activation. A
region located within -518 to -315 bp is crucial for transcriptional activation during
the chemically induced differentiation of MEL cells. The GATA-1 interaction with
the two GATA-1-binding sites in the proximal ALAS2 promoter, located at -118/113 and -98/-93, is also critical to confer erythroid cell specificity. This conclusion
was supported both in vitro, by the elimination of GATA-1 binding upon mutation
of either of the two GATA-1 elements using electrophoretic mobility shift assays
(EMSA) and, in vivo, by the stimulation of the ALAS2 promoter activity of mutated
GATA-1 binding sites-containing constructs in transiently transfected erythroid
cells.
Hypoxia indirectly affects heme production by inducing the erythropoiesis
via erythropoietin and transferrin (43). Hypoxia-inducible factor 1 (HIF-1),
originally identified as a nuclear factor that can bind to the human erythropoietin
gene, plays a vital role in sensing and responding to hypoxia, but has also been
shown to work through direct induction of ALAS2. HIF-1 is implicated in the
transcriptional upregulation of erythropoietin (EPO), transferrin (44), and
transferrin receptor (45), and thus leads to an increase of erythropoiesis and
hematopoietic iron supply. There are two basic helix-loop-helix subunits that
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compose HIF-1, HIF-1

and HIF-1 . HIF-1

is constitutively expressed, but

rapidly degraded under normoxic conditions, while HIF-1 is both constitutively
expressed and stable (46). Thus, it is the amount of HIF-1 that determines the
overall HIF-1 level in a cell. HIF-1 functions by binding HIF-1-responsive
elements in the 5’ regulatory regions of these genes and thereby mediating
transcriptional activation. In 2000, Kramer et al. (42) identified a putative HIF-1responsive element (CACGTG) within the 5’-flanking region of the mouse ALAS2
promoter at position -318 to -323. Since hypoxia induces several HIF-1 target
genes involved in erythropoiesis, and ALAS2 is the rate-limiting enzymes in
heme synthesis, in 2003 Hofer et al. (47) performed the first functional analysis of
oxygen regulation of ALAS2. Nevertheless, despite an upregulation of ALAS2
mRNA by hypoxia as expected, the putative HIF-1-binding site, located at -323/318 of the ALAS2 promoter, did not play a functional role. Thus, hypoxia
induction of ALAS2 was concluded to be HIF-1-independent.
However, in 2011, Zhang et al. (41) looked downstream of ALAS2 and
identified three putative HIF-1-responsive elements located 611, 621, and 741 bp
beyond the ALAS2-encoding region and within the 3’-UTR of the human ALAS2
gene. They found that HIF-1 did bind to all three of the sites, overexpression of
HIF-1

increased ALAS2 expression, and knockdown of HIF-1

by RNA

interference decreased the level of ALAS2 expression. Thus, hypoxia results in a
transcriptional upregulation of ALAS2 that is in fact HIF-1-dependent through
HIF-1 binding sites downstream of the coding region of the ALAS2 gene (41).
The hypoxic upregulation of ALAS2 expression contributed significantly to an
10

increased level of heme synthesis and likely represents an adaptive response to
optimize heme biosynthesis under hypoxic conditions (41). Taken all together,
evidence clearly supports that HIF-1 binds to elements in the 3’-flanking region of
the human ALAS2 gene, and HIF-1 binding directly mediates the hypoxic
induction of the human ALAS2 gene.
It is well established that oxygen level plays a key role in systemic control
of erythropoiesis through feedback regulation of EPO production, which is
increased by tissue hypoxia and decreased by return to normoxia. However, it
appears that hypoxia influences erythropoiesis beyond the known mechanism, in
that red blood cell production is enhanced by low oxygen concentration at many
stages of development. The actions caused by hypoxia on erythroid progenitors
include

enhanced

amplification

and

acceleration

of

their

proliferation,

differentiation, and maturation (48). These effects are associated with a hypoxiainduced gene expression profile, which includes increases in gene expression of
ALAS2 in both cord blood and peripheral blood cell cultures, although increase is
more prominent in cord blood cell cultures (48). GATA-1 expression is also
increased by low oxygen in cord blood culture, and may be part of the
mechanism linking ALAS2 expression to hypoxia. Globin expression is increased
as well (48), which indicates that oxygen concentration is involved in the
synchronization of heme and globin synthesis to efficiently generate hemoglobin.
Sodium butyrate (NaBu) has also been shown to directly regulate ALAS2
transcription.

NaBu

was

first

recognized

to

induce

differentiation

of

erythroleukemic cells in 1975 by Leder et al. (49). In 2008, Han et al. (50)
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examined the molecular basis underlying the NaBu activation of the ALAS2
gene. They confirmed the effect of NaBu not only on transcriptional activation of
ALAS2 in K562 cells, but also in the non-hematopoietic cell lines 293T human
embryonic kidney epithelial cells and A549 human lung adenocarcinoma cells.
They went on to identify Sp1 binding sites in the ALAS2 promoter that mediated
responsiveness to NaBu activation, but that mutations of the GATA-1 sites did
not affect ALAS2 activation by NaBu (50). Furthermore, NaBu treatment led to
an accumulation of Sp1 protein on the ALAS2 promoter, and it is speculated that
histone deacetylase 1 (HDAC1) may be the target of NaBu inhibition that is
responsible for ALAS2 expression (50). This is supported by previous work
showing that the transcription cofactor p300 plays a role in ALAS2 transcription
and activity of its histone acetyltranferase (HAT) is essential (51), and it was
further shown that Sp1 and p300 synergistically upregulated ALAS2 expression,
whereas HDAC1 reduced the synergy dose-dependently (50).
MEL cells can be induced to undergo erythroid differentiation by a variety
of agents including DMSO, hexamethylene bisacetamide (HMBA) and hemin (5257). The involvement of mitogen-activated protein kinases (MAPKs) in the
regulation of erythroid differentiation has been studied in mammalian cell lines
using these inducing agents (58-61) and demonstrates that MAPKs have an
essential function in erythrocyte maturation. Both DMSO (52) and HMBA (53)
increase ALAS2 expression in MEL cells. Treatment of HMBA-induced MEL cells
with U0126, an extracellular-signal-related kinase (ERK) pathway inhibitor,
further increases ALAS2 expression (62). In contrast, treatment with the p38
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MAPK pathway inhibitor SB202190 slightly decreased ALAS2 expression over
time (62). Thus, the ERK signaling pathway suppresses, and the p38 MAPK
signaling pathways promotes the HMBA-induced erythroid differentiation of MEL
cells. It is unclear how MAPKs are acting to control ALAS2 levels, but since
MAPKs can function by regulating the activity of specific transcription factors
through phosphorylation (63), they may be exerting effects through control of
expression, DNA-binding, or transcriptional activity of transcription factors (62).

Regulation of ALAS2 Translation
Discovery of the intriguing properties of ferritin (64), a ubiquitous iron
storage protein, stimulated many insightful studies that helped elucidate the
major mechanisms for sensing and controlling cellular and organismal iron
homeostasis. Initial studies demonstrated that ferritin abundance and synthesis
were iron-responsive (65-67) and that mammalian cells contained a cytosolic iron
sensor that controlled ferritin iron-responsive (65-67) and that mammalian cells
contained a cytosolic iron sensor that controlled ferritin synthesis (68-70). In
1976, the Munro and coworkers (71) demonstrated that iron stimulated ferritin
synthesis by activating the translation of ferritin mRNAs. The next critical step in
studies of ferritin expression involved the identification of an evolutionarily
conserved 28 nucleotide sequence, termed the Iron-Responsive Element (IRE),
which was present in the 5′-UTR of ferritin mRNAs. The IRE proved to be
necessary and sufficient for iron-dependent control of ferritin mRNA translation
(72-74). These observations occurred simultaneously with the discovery of
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cytosolic iron-regulated RNA binding proteins, IRP1 and IRP2, which recognize
the IRE in a sequence and structure specific manner (75,76). A comparison of
the data on ferritin regulation with data on transferrin receptor 1 (TfR1) from Kühn
and associates (77,78), who showed that TfR1 mRNA stability was iron-regulated
and that the regulatory element responsible was present in the 3′-UTR,
suggested the idea of a general post-transcriptional regulatory network
controlling mammalian iron metabolism (79). Further, Klausner and colleagues
(80) then established that IRE-dependent post-transcriptional control was central
to the regulation of cellular iron metabolism in vertebrates (81,82).
A standard IRE stem structure (Figure 1.3) consists of variable sequences
that form base pairs of moderate stability, and folds into an α-helix that is
distorted by the presence of a small bulge in the middle, caused by either an
unpaired C residue or an asymmetric UGC/C bulge/loop (83). The loop at the top
of this stem contains a conserved 5’-CAGUGX-3’ sequence, in which ”X”
represents either an A, C, or U (83). This top loop most likely functions as a
molecular ruler that orients and correctly distances the bulge C from residues in
the loop, allowing flexible residues to participate in sequence-specific interactions
between the IRE and IRPs (84).
In 1991, examination of the immediate promoter of the human ALAS2
gene revealed a putative IRE in the 5’-UTR of the human ALAS2 mRNA that is
not present in the ALAS1 mRNA (30). This IRE motif was shown through gel
retardation analysis to form a protein-RNA complex with cytosolic extracts from
human K562 cells and this binding was strongly competed with IRE transcripts
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from ferritin or transferrin receptor mRNAs (30). Furthermore, a transcript of the
ALAS2 IRE mutated in the conserved loop of the IRE did not readily produce this
protein-RNA complex in gel retardation analyses. These results supported that
the IRE in the ALAS2 mRNA is indeed functional and that translation of the
mRNA during erythropoiesis is regulated by the availability of cellular iron (30). It
was also later confirmed by a separate group that the IRE motif contained in
ALAS2 mRNA is sufficient to confer translational control to a reporter mRNA both
in transfected MEL cells and in vitro (85). Thus, the level of cellular iron during
erythropoiesis plays a significant role in dictating the translation of ALAS2 mRNA,
and this occurs through the interaction with the IRE motif in ALAS2, a motif not
present in ALAS1 mRNA.
Considering that ALAS2 catalyzes the initial reaction for heme
biosynthesis in erythroid cells, the translational repression of its mRNA by IRPs
associates the IRE-IRP system with systemic iron utilization and homeostasis.
This physiological response may be critical to inhibit the accumulation of toxic
protoporphyrin IX when iron is scarce, as is illustrated by two disease
phenotypes. Shiraz mutant zebrafish, which have a genetic defect in glutaredoxin
5 (GLRX5), a gene required for Fe-S cluster assembly, exhibit severe
hypochromic anemia, and show impairment to the regulation of IRP1 that
eventually leads to the translational repression of ALAS2 (86). A comparable
biochemical phenotype is seen in human patients with sideroblastic anemia in
which ALAS2 mRNA translation is suppressed by both IRPs because the
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deregulation of IRP1 was associated with cytosolic iron depletion and
concomitant induction of IRP2 (87).

Figure 1.3. The IRE located in the 5’-UTR of ALAS2 mRNA is a specific binding site
for IRP and is sufficient to mediate iron-dependent translational regulation. The
IREs found in (A.) murine ALAS2 mRNA and (B.) human ALAS2 mRNA. (C.) In the
presence of iron, IRPs do not bind to the IRE, allowing for translation of ALAS2 mRNA.
(D.) In iron-depleted cells, IRP binding to the IRE in the 5′-UTR interferes with
translational initiation.

In 2010, Ye et al. (87) hypothesized that transcriptional remodeling in
response to cell stress may account for systolic iron depletion, which activates
IRPs, repressing ALAS2 synthesis, and thus inhibiting heme synthesis in GLRX5
deficiency. They found that in GLRX5-deficient cells, [Fe-S] cluster biosynthesis
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was impaired and the IRE-binding activity was IRP1 was activated. Also, they
observed increased IRP2 levels, indicative of relative cytosolic iron depletion,
together with mitochondrial iron overload. Decreased ALAS2 levels attributable to
IRP-translational repression were seen in erythroid cells in which GLRX5
expression had been downregulated using siRNA (87). The IRE-IRP system and
its ability to regulate heme synthesis via ALAS2 help to explain why GLRX5
deficiency results in anemia in the zebrafish model and sideroblastic anemia in
humans.

Stability of ALAS2
Regulation of ALAS2 at the protein level have been most notably studied
in terms of oxygen level effects and also in terms of mutations seen in x-linked
sideroblastic anemia (XLSA) patients. In 2005, Abu-Farha et al. (88) noted that
ALAS2 contains a single, highly conserved LXXLAP sequence located at amino
acid residues 515-520, that is not found in the corresponding sequence in ALAS1
(Figure 1.4). This LXXLAP motif, where L is leucine, A is alanine, P is proline,
and X is any amino acid, is a motif found in HIF1-α, which was previously
discussed regarding its ability to upregulate ALAS2 transcription (41), is
destabilized in normoxic conditions, leading to rapid hydroxylation, ubiquitination,
and proteasomal degradation (89,90). A defining feature of this HIF-1
degradation involves its two LXXLAP oxygen regulatory motifs, and its
degradation process is known to be regulated through prolyl-4-hydroxlases that
can hydroxylate the proline residues in the presence of oxygen, which leads to
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ubiquitination of HIF1-α by E3 ubiquitin ligases (89-93). Through this LXXLAP
motif, ALAS2 is regulated by hypoxia at the protein level and thus stabilized in
low oxygen conditions much like HIF-1 (88). Not only is ALAS2 stabilized, but it
is also more resistant to degradation under hypoxic conditions in comparison to
normoxia. Mutation of proline 520 of the LXXLAP motif also caused stabilization
of ALAS2 under normoxic conditions, suggesting that post-translational
modification under normoxic conditions contributes to the degradation of ALAS2.
Furthermore, mutation of proline 520 in vitro eliminated the ability of ALAS2 to be
ubiquitinated in normoxic conditions (88). The mutation of proline 520 mimicked
the lack of ubiquitination and stability of wild-type ALAS2 observed under hypoxic
conditions. Thus, through its LXXLAP motif, ALAS2 can be stabilized under
hypoxic conditions and resist ubiquitination and subsequent proteasomal
degradation (88).

Figure 1.4. Multiple alignment of ALAS2 and ALAS1 C-terminal amino acid
sequences from multiple organisms. The LXXLAP motif is well-conserved in ALAS2,
but not ALAS1. The extended C-terminus is not present in R. capsulatus ALAS, for
which there is the only solved crystal structure of ALAS, and thus the tertiary structure of
the extended C-terminus is unknown.
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Another noteworthy region of ALAS2 is within the C-terminus of ALAS2, of
which the final 33 amino acids are conserved in higher eukaryotes, but are not
present in prokaryotes (Figure 1.4). Since the only crystal structure of ALAS2 that
has been solved is of R. capsulatus (94), the tertiary structure of the C-terminus
remains a mystery. However, it appears that the ALAS2 C-terminus may have a
function in higher eukaryotes, as mutations in ALAS2 corresponding to the Cterminus have been associated with both XLSA and x-linked erythropoietic
porphyria (XLEPP) (95-97). In 2012, Kadirvel et al. (97) studied novel missense
mutations in the 11th exon of the human ALAS2 gene associated with XLSA
along with a human ALAS2 variant with a complete deletion of its C-terminus.
Using a combination of experiments measuring in vitro enzymatic activity using
bacterially expressed recombinant proteins and in vivo experiments evaluating
catalytic activity by comparing the accumulation of porphyrins in eukaryotic cells
stably expressing mutant ALAS2 enzyme tagged with FLAG, they concluded that
the C-terminus of the human ALAS2 protein acts as an intrinsic regulator of
catalytic activity and protein stability (97). Although there has been speculation of
allosteric regulation, potentially through binding of iron or heme at a particular
conserved “C-X-X-C” motif (98), and speculation of the potential for posttranslational modifications in the C-terminus (98), it is still unclear how the Cterminal region is able to suppress the enzymatic activity, and how mutations in
the C-terminus can cause changes in that activity and the stability of the enzyme.
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Mitochondrial Import of ALAS2
In mammalian cells, anabolic and catabolic pathways are normally
confined to a single cellular compartment unless the process involves import or
export of products or substrates. The tetrapyrrole biosynthetic pathway is
atypical, as its first step and its last three steps are catalyzed by mitochondrial
enzymes, whereas the intermediate four steps are catalyzed by cytosolic
enzymes (99). All eight of the pathway enzymes are encoded in the nucleus and
are synthesized in the cytosol with the mitochondrially located proteins being
post-translationally translocated to their appropriate mitochondrial space. For
example, coproporphyrinogen oxidase is located in the space between the inner
and outer mitochondrial membranes (100,101), protoporphyrinogen oxidase is
thought to be either in the space between the inner and outer mitochondrial
membranes or associated with the matrix side of the inner mitochondrial
membrane (102), and ferrochelatase is associated with the matrix side of the
inner mitochondrial membrane (103). ALAS is located in the mitochondrial matrix
where its substrates, glycine and succinyl-CoA, are found (31,104). A preenzyme of ALAS is synthesized by cytosolic ribosomes, which is then imported to
and processed within the mitochondria to yield the mature form of the enzyme
(105-107). This pre-enzyme ALAS has a mitochondrial import sequence on its Nterminus that is vital for recognition by the protein import machinery located in the
mitochondrial membrane (108).
Most mitochondrial proteins are encoded in the nucleus and synthesized
in the cytosol as precursor polypeptides, larger than the corresponding mature
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forms due to the additional amino-terminal residues comprising leader peptides.
These precursor proteins are post-translationally recognized by mitochondria,
translocated across one or both mitochondrial membranes by an energydependent mechanism, and processed to their mature size by proteolytic
removal of the amino-terminal leader peptides (109,110). The leader peptides
are required for mitochondrial import, supported by the fact that precursors
incubated with isolated mitochondria are imported, whereas the corresponding
mature proteins either fail to be taken up or interfere with uptake of the
precursors (110,111). Whether leader sequences function independently or in
concert with sequences in the mature portions of the precursors was unknown
until 1985, when Horwich et al. (112) demonstrated that the leader peptide is
sufficient to direct mitochondrial import. Researchers employed gene fusion
techniques to join the coding sequence of the precursor of the mitochondrial
matrix enzyme ornithine transcarbamylase with the coding sequencing for the
cytosolic enzyme dihydrofolate reductase. They showed that the chimeric protein
was

recognized

by

mitochondria,

translocated

by

mitochondria,

and

proteolytically processed (112). Since this discovery, the mitochondrial import
field has expanded significantly and become more complex than previously
imagined, including the characterization of several classes of precursor proteins
containing distinct targeting signals that are directed to different import routes
(113).

However,

mitochondrial

import

facilitated

by

an

amino-terminal

presequence on the cytosolic protein remains the most recognized means of
mitochondrial protein targeting, and it is by this method that ALAS is imported to
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the mitochondria.
Human ALAS2 is synthesized as a precursor of molecular mass 65 kDa
with an amphipathic presequence of 49 amino acids (114). In general,
mitochondrial presequences do not share any primary sequence identity (108),
but they do show a statistical bias of positively charged amino acid residues,
provided mostly through arginine residues (115). The positive charges in the
presequences have the potential to interact with the negatively charged surface
of mitochondrial membranes (116), the mitochondrial import receptor (117), and
the

mitochondrial

processing

peptidase

(118,119).

Mitochondrial

leader

sequences also share an ability to form an amphiphilic, α-helix (115,120,121). As
much of heme synthesis depends on proper translocation of the enzymes active
in the mitochondria, the mechanism of mitochondrial import of ALAS has been
investigated in great detail, especially in terms of a role for feedback inhibition by
heme.

Heme Inhibition of ALAS Mitochondrial Import
Researchers of ALAS in the 1960s and 1970s noted that the intracellular
concentration of ALAS1 is normally low (122), but that an extensive selection of
xenobiotics and steroids significantly increase its activity in mammalian (123) and
avian liver cells (122,124-126), and cause the synthesis of high concentrations of
porphyrins (127). Granick and Urata (122) produced chemically-induced
porphyria in chick embryo liver cells that resembled human acute intermittent
porphyria biochemically and noted that a number of chemical inducers are known
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to precipitate attacks of the disease in susceptible individuals. Immunological
studies later showed that, in experimentally induced porphyria, the synthesis of
ALAS occurs de novo (128) and heme, the final product of the pathway, inhibits
enzyme induction (125-127,129).
Although there was a general agreement that heme plays an important
role in the physiological control of ALAS activity (126,127,129,130), there was no
such consensus on the mechanism of its action, and many different schemes
were suggested. Granick (127) originally proposed that heme acts as a corepressor for ALAS transcription, and that chemical inducers acted as heme
analogues that compete for the repressor protein, thus preventing heme from
repressing ALAS mRNA transcription (127). However, later studies by Sassa and
Granick (131) and Tyrrell and Marks (129) suggested that, contrary to this
transcriptional theory, heme exerted its effect at a post-transcriptional stage. The
finding that there was apparently no concentration-dependent competition
between heme and porphyria-inducing chemicals (124,131) further argued
against the original concept of Granick (127). The groups of Ohashi and Kikuchi
(130) and Hayashi et al. (132) proposed that, in adult chickens, heme exerts its
effect by controlling transport of cytoplasmically synthesized ALAS into the
mitochondria. However, heme did not affect ALAS transport in embryonic chick
liver (126,129,131).
In 1980, Srivastava et al. (133,134) reevaluated the effects of heme on
ALAS induction by using a newly developed system of isolated chick-embryo
liver cells. In this system, they showed that initiation of ALAS induction requires
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the presence of a chemical inducer, in this case 2-allyl-2-isopropylacetamide, but
that continued presence of this inducer was not necessary, provided heme
synthesis is prevented. This was compatible with a scheme in which 2-allyl-2isopropylacetamide causes a depletion of intracellular heme, and in which heme
is the principal controlling agent in the induction of ALAS. Their data conflicted
with those of Tyrrell and Marks (129) and showed that, at a concentration of 20
nM, hemin will completely inhibit ALAS induction and that this effect is primarily
at the level of transcription.
Furthermore, Sassa and Granick (131) had estimated that the intracellular
concentration of heme in chick embryo liver cells is in the order of 50-100 nM,
which was sufficient to completely inhibit ALAS synthesis and to prevent
induction of hepatic porphyria. At this time, the conclusion was that in chickembryo liver cells, induction of ALAS synthesis was being primarily regulated by
the intracellular concentration of heme and that the effect of heme on the
synthesis of ALAS is at the level of transcription. Also, they felt that translational
effects seen at higher concentrations were more likely related to heme toxicity.
However, through the discovery of a short amino acid sequence to which heme
binds, termed a heme regulatory motif (HRM), scientists were able to specifically
examine effects of heme on transport of precursor ALAS into the mitochondria
(105,135,136).
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Heme Regulatory Motifs of ALAS
Both precursor ALAS1 and ALAS2 in mammals each contain three hemebinding HRMs consisting of CP-based short amino acid sequences (Figure 1.5)
(137), a motif found in many proteins and shown to function as heme-oxygen
sensors in bacteria (138), yeast (139,140), and mammals (136,141,142). The
HRMs in ALAS were initially identified to contain the sequence R/L/N-C-PL/V/I/F-L/M, where the cysteine and proline residues are invariable (136),
although some minor substitutions are present in some species (143). Two of
these motifs are contained in the region of the leader sequence that is
proteolytically removed in the mitochondria, and the third is contained in the Nterminus of the mature enzyme (Figure 1.6). In human ALAS1, the motif locations
are referred to by their cysteine residues and are at amino acid positions C8,
C33, and C108. On the basis of in vitro translocation experiments with isolated
mitochondria and ALAS2 protein, the two heme-binding motifs in the leader
sequence have been proposed to bind heme and prevent translocation of
precursor ALAS2 into the mitochondrion (136). Dailey et al. (144) studied the
putative roles of all three HRMs in human ALAS1 in mitochondrial import,
revealing both that each of the motifs play an independent functional role as a
heme sensor, and that the HRMs function synergistically to achieve maximal
heme inhibition. They demonstrated, through a collection of cysteine to serine
mutations in human ALAS-GFP expressed in murine hepatoma cells, that
intracellular translocation of ALAS1 is heme-sensitive and that this sensitivity is
dependent on the presence of at least one of the heme-binding motifs. They had
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not expected the third HRM located in the mature protein to be functional due to
its distance, over 50 amino acid residues, from the targeting sequence. They
hypothesized that given that little heme is present in the mitochondrial matrix
compartment, it is plausible that any regulatory role for this particular HRM would
be for translocation and not for enzyme inhibition or inhibition of cofactor binding

Figure 1.5. The N-terminal amino acid sequence of human ALAS1 and ALAS2
indicating the location of the HRMs. In human ALAS2, shown in black, the three
HRMs, shown in bolded red, are located at C11, C38, and C70. In human ALAS1,
shown in blue, HRMs are located at C8, C33, and C108. The N-terminus is the least
similar domain between ALAS1 and ALAS2.

by the precursor protein. Furthermore, it may be that the binding of heme at this
site prevents the protein from folding properly, which would make it more
susceptible to proteolytic processing in the cytoplasm (144).
Lathrop and Timko (136) were the first to show that the conserved
cysteines of the HRMs in murine ALAS2 are involved in heme inhibition of
transport into the mouse mitochondria. In mouse ALAS2, the motif locations are
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at amino acid positions C11, C38, and C70. In Lathrop and Timko’s initial
experiments, the deletion of the third HRM (C70) that is normally present in Nterminus of the mature form of ALAS2 did not significantly affect mitochondrial
transport, and thus they continued experimentation of only the C11 and C38
HRMs. Since conserved cysteine residues are often involved in the coordination
of heme to its apoprotein (145,146), they mutagenized the C11 and C38 residues
to serines and evaluated the effects of various hemin concentrations up to 25 μM
on mitochondrial transport. Using hemin concentrations of 10 μM and 25 μM,
they found that mutations of cysteines at both sites completely eliminated the
heme inhibition of transport, while mutation of only either C11 or C38 resulted in
a 75 to 82% inhibition of transport using 25 μM of hemin (136).
Goodfellow et al. (114) reinforced the functional role of the HRMs in
ALAS2 by providing the structural data demonstrating that a heme-peptide
interaction occurs between hemin and the presequence of murine ALAS2.
However, some discrepancies on the functional role of the HRMs in ALAS2 still
exist. In 2004, Munakata et al. (147) compared the role of the HRMs in the
heme-regulated transport of the ALAS1 and ALAS2 in vivo. They constructed a
series of mutants of rat ALAS1 with mutated cysteines and expressed the
constructs in quail QT6 fibroblasts through transient transfection to examine
mitochondrial import of the enzymes in the presence of hemin (147). While they
found both that hemin inhibited the mitochondrial import of wild-type ALAS1 and
that this inhibition was reversed by the mutation of all three HRMs in the enzyme,
exogenous hemin did not affect the mitochondrial import of the ALAS2 under the
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Figure 1.6. Depiction of human ALAS1 and ALAS2 protein domains. Region A
represents the presequence, region B represents the catalytic core domain, and region
C represents the mature mitochondrial protein. The dotted lines represent the locations
of the three HRMs in the respective ALAS proteins. In the entire precursor protein,
56.2% of the amino acid residues are identical. However, the sequences are more
similar in their catalytic core regions, in which 72.2% of amino acids are identical. The
presequence is the most variable region of amino acid sequence.

same experimental conditions (147). The differences between ALAS1 and
ALAS2 may be attributed to the difference in their biological roles, observing that
it may be the activity of ALAS1 is regulated through the inhibition of mitochondrial
import by the intracellular concentration of heme, whereas the activity of ALAS2
is mainly regulated translationally by the intracellular concentration of iron.
Addtionally, free heme in erythroid precursors may never reach high enough
concentrations to be able to inhibit mitochondrial import of ALAS2, since most
heme molecules are bound to globin. In conclusion, the ability of heme to control
mitochondrial import is well established for ALAS1, but heme inhibition on
mitochondrial import for ALAS2 remains controversial.
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Diseases associated with mutations in ALAS2
Although there are no known genetic diseases associated with a mutation
in the gene encoding ALAS1, there are two disease states associated with
mutations in the gene encoding ALAS2—XLSA, the most common inherited
sideroblastic anemia (148), and XLEPP (96). In XLSA, there is a decreased
function of the ALAS2 enzyme. XLSA is characterized by anemia, which is a lack
of healthy erythrocytes, and iron accumulation in perinuclear mitochondria of
erythroblasts in the bone marrow, called ring sideroblasts, which are present as a
result of impaired iron utilization (95,149). The first case of microcytic,
hypochromic anemia with an X-linked pattern of inheritance was described in
1945 (150), but it was not until 1992 that Cotter et al. (151) established that the
genetic basis for XLSA lies on ALAS2 genetic mutations. While, as expected,
XLSA predominantly affects males, females are also affected when the mutant
allele is expressed as a result of lyonization (152).
Management of XLSA symptoms involves not only treatment of anemia,
but also prevention and treatment of iron overload (153). Approximately 75% of
XLSA patients have mutations in ALAS2 that affect its binding to its PLP cofactor.
These patients, termed pyridoxine-responsive, can be placed on a pyridoxine
regimen to improve the function of the ALAS2 (152,153). Iron overload is treated
based on the severity of the anemia. If the anemia is mild, then regular
phlebotomies are performed as a preventive measure against iron overload;
however, if the anemia is severe, then iron chelating agents, such as
deferoxamine, are the preferred treatment (152).
29

In contrast to XLSA, XLEPP in characterized by an increase in function of
the ALAS2 enzyme (96). These gain-of-function mutations result in an increase
of PPIX in the bone marrow and circulating erythrocytes, and cause extreme
skin photosensitivity. However, XLEPP was only recently identified because the
symptoms of XLEPP are nearly identical to those of erythropoietic porphyria
(EPP), which is caused by mutations in ferrochelatase that impair its function.
Discovery of mutations in ALAS2 leading to porphyria demonstrated the
association of each of the eight enzymes of heme biosynthesis with a unique
porphyria (Table 1.1).

Acute porphyrias, also known as hepatic porphyrias,

primarily affect the nervous system. Cutaneous porphyrias, also called
erythropoietic

porphyrias,

primarily

affect

the

skin

resulting

in

photosensitivity.The biochemical distinction between XLEPP and EPP that
ultimately led to the discovery of XLEPP is the accumulation of zincprotoporphyrin in red blood cells of XLEPP patients, an increase not seen in
EPP patients (96). The high zinc-protoporphyrin concentrations can be
explained considering that ferrochelatase can use Zn(II) as an alternate metal
ion substrate (154), and the overactive ALASs present in XLEPP create an
imbalance in the ratio of Fe(II) to protoporphyrin. Due to the substrate
stoichiometric mismatch, Zn(II) is incorporated into protoporphyrin (155). Thus,
measurement of zinc-protoporphyrin levels is the key for diagnosis of XLEPP.
All mutations that have been characterized from patients with XLEPP are
located at the C-terminus of the ALAS2 mature protein, which is highly
conserved in mammals, implying that the C-terminal region of ALAS plays a vital
30

role in its regulation, activity, and /or stability. The increased catalytic efficiencies
and substrate affinities of purified, recombinant human ALAS2 variants
harboring some of the known XLEPP mutations versus those of wild-type ALAS2
were consistent with the proposal that the XLEPP mutations in ALAS2 produced
enzyme variants more active than ALAS2 in healthy individuals (156,157). In
addition, the identification of a C-terminal, 33-amino acid sequence as the
minimal size domain contributing to the gain-of-function of ALAS2 (156,158)
supports the previously proposed molecular mechanism for the control of ALAS
activity (98). However, the mechanism by which mutations in the C-terminus
result in increased ALAS2 activity have yet to be fully elucidated.

Table 1.1. Genes encoding heme biosynthesis enzymes implicated in inherited
porphyrias.
Gene

Porphyria

Classification

ALAS2

X-linked erythropoietic protoporphyria (XLEPP)

Cutaneous

ALAD

ALA dehydratase deficient porphyria (ALAD-P)

Acute

HMBS

Acute intermittent porphyria (AIP)

Acute

UROS

Congenital erythropoietic porphyria (CEP)

Acute

UROD

Porphyria cutanea tarda (PCT)

Cutaneous

CPOX

Hereditary coproporphyria (HCP)

Cutaneous

PPOX

Variegate porphyria (VP)

Acute

FECH

Erythropoietic protoporphyria (EPP)

Cutaneous

Content of this dissertation
This dissertation focuses on mutations in ALAS2 that lead to an increased
activity of the enzyme. First, we evaluate whether mALAS2 variants with
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increased activity could be useful for production of the photosensitizer PPIX for
PDT. Secondly, to understand the mechanisms behind the symptoms of XLEPP,
XLEPP variants with mutations in the ALAS2 C-terminus are characterized in
terms of their catalytic activity, substrate affinities, thermostability, cellular
activity, and structure. Thirdly, INH, an antibiotic used to treat tuberculosis, is
evaluated as an inhibitor for human ALAS2. The conclusions presented in each
chapter add to the general knowledge of the ALAS-catalyzed reaction, provide
insight into the mechanism of XLEPP, and provide evidence for INH as an
inhibitor of ALAS2, which has potential for treating porphyria patients.
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CHAPTER 2: EXPRESSION OF MURINE 5-AMINOLEVULINATE SYNTHASE
VARIANTS CAUSES PROTOPORPHYRIN IX ACCUMULATION AND
LIGHT-INDUCED CELL DEATH IN MAMMALIAN CELLS
Abstract
5-Aminolevulinate synthase (ALAS; EC 2.3.1.37) catalyzes the first
committed step of heme biosynthesis in animals. The erythroid-specific ALAS
isozyme (ALAS2) is negatively regulated by heme at the level of mitochondrial
import and, in its mature form, certain mutations of the murine ALAS2 active site
loop result in increased production of protoporphyrin IX (PPIX), the precursor for
heme. Importantly, generation of PPIX is a crucial component in the widely used
photodynamic therapies (PDT) of cancer and other dysplasias. ALAS2 variants
that cause high levels of PPIX accumulation provide a new means of targeted,
and potentially enhanced, photosensitization. In order to assess the prospective
utility of ALAS2 variants in PPIX production for PDT, K562 human
erythroleukemia cells and HeLa human cervical carcinoma cells were transfected
with plasmids encoding ALAS2 variants with greater enzymatic activity than the
wild-type enzyme. The levels of accumulated PPIX in ALAS2-expressing cells
were analyzed using flow cytometry with fluorescence detection. Further, cells
expressing ALAS2 variants were subjected to white light treatments (21-22 kLux)
for 10 minutes after which cell viability was determined. Transfection of HeLa
cells with expression plasmids for murine ALAS2 variants, specifically for those
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with mutated mitochondrial presequences and a mutation in the active site loop,
caused significant cellular accumulation of PPIX, particularly in the membrane.
Light treatments revealed that ALAS2 expression results in an increase in cell
death in comparison to aminolevulinic acid (ALA) treatment producing a similar
amount of PPIX. The delivery of stable and highly active ALAS2 variants has the
potential to expand and improve upon current PDT regimes.

Introduction
The first committed step of heme biosynthesis in non-plant eukaryotes and
some prokaryotes, the pyridoxal 5’-phosphate (PLP)-dependent condensation of
glycine and succinyl-coenzyme A to generate 5-aminolevulinate (ALA),
coenzyme A (CoA), and CO2, is catalyzed by 5-aminolevulinate synthase (ALAS)
(1,2). This reaction is directly coupled to the citric acid cycle via the substrate
succinyl-CoA and is the key regulatory step of heme biosynthesis (3). In
mammals, two chromosomally distinct genes each encode an ALAS isoenzyme,
and the two isoenzymes are differentially expressed in a tissue specific manner
(4). The human gene for the non-specific or housekeeping isoform, ALAS1, is
located on chromosome 3 (5,6), and is expressed ubiquitously in all tissues (7).
The gene encoding the erythroid specific isoform, ALAS2, is located on the xchromosome (6,8) and is expressed only in developing erythroblasts (7).

The two ALAS isoenzymes are translated as precursor proteins with Nterminal mitochondrial matrix import signal sequences that are proteolytically
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cleaved following importation to yield the mature enzymes (9-12). The activity of
the enzyme is only manifested upon localization to the mitochondrial matrix, as
this is where the substrate succinyl-CoA is produced (13-16). An important
aspect of the import sequences in both ALAS1 (17) and ALAS2 (18) are the
presence of heme-regulatory motifs (HRMs), which consist of short amino acid
sequences characterized in part by adjacent cysteine-proline (CP) residues (19).
HRMs confer heme-binding properties and have been shown to function as
heme-oxygen sensors in bacteria (20), yeast (21) and mammals (18,22,23). In in
vitro translocation experiments with isolated mitochondria and ALAS2 precursor
protein, the two heme-binding motifs in the leader sequence, corresponding to
C11 and C38 in murine ALAS2 (mALAS2), were reported to bind heme and
prevent translocation of precursor ALAS2 into the mitochondrion (18). Structural
and biochemical data have also demonstrated that a heme-peptide interaction
occurs between hemin and the presequence of ALAS2 (24), further indicating the
potential of heme to act as a feedback inhibitor of the pathway by preventing the
mitochondrial import of precursor ALAS2 when heme levels are sufficient for
cellular requirements.
Much of what we know about the chemical and kinetic mechanisms of
ALAS2 comes from in vitro enzymatic assays that have helped establish and
define the microscopic steps of the ALAS-catalyzed reaction, including the rates
of glycine and succinyl-CoA binding, formation of the quinonoid intermediates,
and product release (2,25-28). These studies, performed using mALAS2 purified
from E. coli cells expressing the recombinant mature enzyme, have led to an
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understanding of the importance of specific regions and single amino acid
residues in the intrinsic activity of ALAS2 (29-35). Generally, a mutation made to
an amino acid predicted to be of functional importance causes a decrease in
activity of the enzyme. For example, K313 of mALAS2 was identified as the
amino acid involved in the Schiff base linkage with the PLP cofactor (36), and
mutations in K313 completely abolish measurable activity of mALAS2 under
standard assay conditions (29,37). However, some mutations in mALAS2 cause
significantly increased activity of the enzyme, as demonstrated both using
purified enzyme (31,35), and in bacteria when expressing plasmids encoding the
variant enzymes (35). These mutations are all located in an extended
conformation region termed the active site loop (Y422-R439), which is predicted
to act as a “lid” over the active site following substrate binding (35). Thus, ALAS
is thought to undergo a conformational change from an open conformation, in
which the substrates glycine and succinyl-CoA can bind in the active site, to a
closed conformation, during which the products ALA, CoA, and CO 2 are formed
(25,28). When the reaction is complete, the active site loop reopens, and the
products are released. It is the opening of the active site loop to allow product
release that limits the overall rate of the enzymatic reaction (2,25,27). Based on a
combination of kinetic (25,28) and structural modeling studies (38), it was
proposed that mutations in the active site loop can lead to hyperactive forms of
ALAS, defined as those with at least a 10-fold increase in catalytic efficiency
toward one or both substrates, by accelerating reversion to the open loop
conformation upon product formation (35).
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Since

ALAS

catalyzes

the

rate-determining

step

of

tetrapyrrole

biosynthesis in mammals (2,25), overexpression of ALAS in prokaryotic (35) and
eukaryotic cells (39) results in accumulation of the photosensitizing heme
precursor, protoporphyrin IX (PPIX). This property has potential for applications
of ALAS or ALAS variants in photodynamic therapy of tumors and other nonmalignant dermatological indications, such as acne vulgaris, psoriasis, and
scleroderma (40,41). In this study, we transfected mammalian cells with mALAS2
variants and measured PPIX accumulation using fluorescence activated cell
sorting (FACS). We identified the R433K variant with additional mutations of the
HRMs in the presequence as the variant causing the most cellular PPIX
accumulation. Subsequently, we used the variants causing the most PPIX
accumulation to study the cell death caused by the PPIX toxicity and
photosensitization.

Materials and Methods
Materials—5-Aminolevulinic acid hydrochloride (ALA) was purchased from
Acros Organics (Morris Plains, NJ), and dissolved in distilled water at a
concentration of 10 mg/mL. Glycine, purchased from Fisher Chemical (Fairlawn,
NJ), was dissolved in phenol red-free culture medium purchased from Mediatech,
Inc. (Manassas, VA) to give a stock concentration of 1 M. Paclitaxel (6 mg/mL
stock in DMSO) was graciously provided by the laboratory of Dr. Scott Antonia
(H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL), and was
diluted in culture medium directly before use. Deferoxamine mesylate, purchased
60

from Sigma (St. Louis, MO), was dissolved in distilled water to create a 10 mM
stock solution. Propidium iodide, 4′,6-diamidino-2-phenylindole (DAPI) and
kanamycin sulfate were purchased from Acros Organics (Morris Plains, NJ), and
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium

bromide

(MTT)

was

purchased from Sigma-Aldrich (St. Louis, MO). BmtI and BamHI restriction
enzymes were obtained from New England BioLabs, Inc. G418 sulfate was
procured from Mediatech, Inc. (Manassas, VA).

Plasmids—The precursor ALAS2 cDNAs were individually subcloned into
the multiple cloning site of the pIRES2-ZsGreen1 vector (purchased from
Clontech Laboratories, Inc. Mountain View, CA) using the BmtI and BamHI
restriction sites. Digested ALAS2-encoding fragments were ligated into the
digested pIRES2-ZsGreen1 vector using T4 DNA ligase and ligase buffer
(Thermo Scientific Fermentas (Waltham, MA)). Electrocompetent BL21(DE3)
cells were transformed by electroporation with the ligated plasmid DNA and
selected by spreading them on LB agar medium containing 10 g/mL kanamycin
sulfate. Plasmid DNA was purified from a single colony using a QiaPrep Spin
Miniprep kit (Qiagen Inc.; Germantown, MD), and the sequence of the cloned
DNA was verified by Genewiz, Inc. (New Brunswick, NJ).

Cell culture—K562 human immortalized myelogenous leukemia cells
(ATCC) were maintained in RPMI-1640 culture medium, purchased from
Mediatech, Inc. (Manassas, VA), with 10% fetal bovine serum (FBS; purchased
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from Thermo Scientific Waltham, MA), gentamicin (50

g/mL), penicillin (60

μg/mL) and streptomycin (100 g/mL) at 37°C in a humidified incubator with 5%
CO2. HeLa human cervical carcinoma cells (ATCC) were maintained in DMEM
culture medium with 4.5 g/L glucose, L-glutamine, and sodium pyruvate
(Mediatech, Inc.; Manassas, VA), with 10% fetal bovine serum (FBS), gentamicin
(50 μg/mL), penicillin (60 μg/mL) and streptomycin (100

g/mL) at 37°C in a

humidified incubator with 5% CO2.

Stable transfection of K562 human erythroleukemia cells—K562 cells
were transfected with Lipofectamine™ LTX and PLUS™ Reagent, purchased
from Invitrogen (San Jose, CA), according to the supplier’s optimized protocol for
K562 cells. On the day of transfection, a hemocytometer and trypan blue staining
were used to count the cells and determine culture density and viability. In a 6well plate, K562 cells (5 x 105 cells per well) were seeded in a 6-well plate at a
volume of 2 mL of RPMI-1640 growth medium with 10% FBS 30 minutes prior to
transfection. For each transfection, 2.5 μg of DNA was added into 500 μL of
RPMI medium without serum. 2.5 μL of PLUS™ reagent (at a 1:1 ratio to DNA)
was then added directly to the diluted DNA. After gentle mixing and a 10 minute
incubation at room temperature, 10 μL of Lipofectamine™ LTX was added into
the diluted DNA solution, mixed gently and incubated for 35 minutes at room
temperature

to

form

DNA-Lipofectamine™

LTX

complexes.

The

DNA-

Lipofectamine™ LTX complexes were added dropwise to each well containing
cells and mixed gently by manually rocking the plate back and forth. 24 hours
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after transfection, the cells were pelleted by centrifugation at 400xg and
resuspended in RPMI-1640 culture medium with 10% FBS, gentamicin (50
g/mL) and the selection antibiotic, G418 sulfate (500

g/mL). Every 2-3 days,

the cells were pelleted and resuspended in fresh medium with 10% FBS,
gentamicin (50 μg/mL), and G418 sulfate (500 μg/mL). Assays were performed
2-6 weeks after the start of selection.

Transient transfection of HeLa cells—On the day prior to transfection,
HeLa cells were trypsinized and counted. Approximately 2 x 104 cells were
seeded into each well of a 24-well plate in 0.5 mL of DMEM. Cell density was
~30-50% confluent on the day of transfection. For each transfection, 250ng of
DNA was diluted into 100 μl of DMEM without serum. 1 μl of Lipofectamine™
LTX was added into the diluted DNA solution, mixed gently and incubated for 3045 minutes at room temperature to form DNA-Lipofectamine™ LTX complexes.
The DNA-Lipofectamine™ LTX complexes were added dropwise to each well
containing cells and mixed gently by manually rocking the plate back and forth for
a few seconds. After 4 hours of incubation with the DNA-Lipofectamine LTX
complexes, the medium was aspirated out of each well and fresh DMEM with
10% FBS, gentamicin (50

g/mL), penicillin (60 μg/mL) and streptomycin (100

g/mL) was added to each well of cells. Cells were incubated at 37°C in a CO2
incubator for 24 or 48 hours post-transfection before assaying.
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Preparation of cells for FACS and quantitation of PPIX—While K562 cells
were suspended in phenol red-free medium, HeLa cells were washed, scraped
and resuspended in phosphate-buffered saline (PBS; 80 mM disodium hydrogen
orthophosphate, 20 mM sodium dihydrogen orthophosphate, 100 mM sodium
chloride, pH 7.5) before pipetting into BD Falcon tubes with cell strainer caps.
Preparation of either K562 or HeLa cells for FACS was done under very low light
conditions (1-2 Lux as measured by a Pyle PLMT68 light meter) in order to
minimize phototoxicity caused by PPIX accumulation. FACS analyses were
performed using a BD LSR II Analyzer (Becton, Dickinson, and Company) and
FACSDiva Version 6.1.3 software. ZsGreen1 emission was measured between
515 nm and 545 nm (530/30BP filter) when cells were excited using the 488 nm
laser. In order to eliminate any background red fluorescence, the 633 nm-red
laser was blocked during the collection of the PPIX emission data. PPIX emission
was determined in the 619 nm and 641 nm range (630/22BP filter) when cells
were excited with the 405 nm laser. Forward-scatter (FSC) versus side-scatter
(SSC) dot plots were used to gate the whole cells and thus remove the
contribution of the cell debris from the population being examined. A minimum of
10,000 of the gated whole cells were then depicted in dot plots of SSC versus
ZsGreen1 fluorescence, and the “green-fluorescent population” gate was defined
based on untransfected HeLa cells as negative controls. Dot plots of SSC versus
PPIX fluorescence were used to define the PPIX-accumulating cells for both the
“green-fluorescent” and the “non-green fluorescent” populations. The PPIX gating
was based on the negative control for PPIX, the pIRES2-ZsGreen1 vector64

expressing cells. PPIX fluorescence values were normalized for transfection
efficiency using the corresponding ZsGreen1 fluorescence value. Normalized
fluorescence values were obtained by first dividing the mean PPIX fluorescence by the
mean ZsGreen1 fluorescence for each cell population and secondly dividing by the
mean PPIX fluorescence/ZsGreen1 fluorescence ratio of the pIRES2-ZsGreen1transfected cells.

Light exposure assays—HeLa cells in 24-well plates were transfected 48
hours prior to FACS analysis. Cells were washed twice with PBS and placed on
ice (to prevent overheating) underneath a Sylvania incandescent flood lamp
(150W, 120V) for 10 minutes. Light intensity at the samples was measured
before each light exposure experiment using a Pyle PLMT68 light meter, and it
was between 21-22 kLux for all experiments. The samples were resuspended
and pipetted into tubes with cell strainer caps and analyzed first for ZsGreen1
and PPIX fluorescence (as described above), and then for cell viability. In order
to determine the statistical significance of cell death directly attributable to
mALAS2-induced PPIX accumulation and phototoxicity, samples were compared
to the ZsGreen1 controls during one-way ANOVA evaluations.

Cell

viability

assays—Cell

death

was

assessed

by

measuring

incorporation of either propidium iodide or DAPI into nuclear DNA, as these
fluorescent dyes cross the plasma membrane in dying cells much more efficiently
than in live cells. HeLa cell cultures were independently incubated with the
fluorescent DNA-binding dyes propidium iodide (10 μg/mL) and DAPI (10 μg/mL)
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for 5 min at 22oC. The cells were then analyzed by determining the fluorescence
intensities using FACS. Fluorescence emission of nucleic acid-bound propidium
iodide was measured between 585 nm and 625 nm (605/40BP filter) upon
excitation of the cells using the 488 nm laser, while DNA-bound DAPI emission
was measured between 440 nm and 460 nm (450/20BP filter) following excitation
of the cells at 375 nm. Dot plots of SSC versus propidium iodide or DAPI
fluorescence were used to define the respective gates, which were based on the
control samples in which no propidium iodide or DAPI were added. Cell viability
was independently determined using the MTT dye reduction assay as described
elsewhere (42,43). HeLa cells (5 x 103 cells per well) were seeded in 96-well
plates, and on the following day were transfected with plasmids encoding
mALAS2 variants as described above. Twenty-four hours after plasmid
transfection, or 4 hours after addition of 100 M ALA, cells were exposed to light
for 10 minutes. The culture medium was pipetted out, 50 μL of 2 mg/mL MTT
was added to each well, and cells were incubated for an additional 4 hours at
37 C. Upon solubilization of the cells with DMSO (100 μL/well) during a 10
minute incubation, the solubilized, MTT-treated cells were thoroughly mixed by
pipetting several times, and absorbance was measured at 540 nm using a
μQuant plate reader (Bio-Tek Instruments, Inc.). For control and ALA-treated
cells, cell death was calculated by dividing the number of DAPI-stained cells by
the total number of cells. For ZsGreen1-, WT-, HPVT-, and R433K-expressing
cells, cell death was calculated from the ZsGreen1-positive cell populations by
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dividing the number of DAPI-stained cells by the total number of ZsGreen1positive cells.

Confocal

fluorescence

microscopy—HeLa

cells

were

grown

in

Thermoscientific™ Nunc™ Labtek™ sterile 4-well chambered coverglass until
50% confluent, and then transfected as described above. Six hours later, the
culture medium was supplemented with glycine to yield a final concentration of
100 mM, and immediately before obtaining confocal fluorescence microscopy
images of the cells, the medium was removed from the wells and the cells were
washed with PBS three times. Live cell imaging was performed using a 3iOlympus spinning disk confocal microscope operated by Slidebook 5 software
and equipped with a Photometrics Evolve EMCCD camera. The filter block used
consisted of a 350/50 nm excitation filter, a BS400 beamsplitter, and a 630/75
nm emission filter.

Results
Transient expression of mALAS2 variants causes accumulation of PPIX in
HeLa cells—HeLa cells were transfected with mALAS2-encoding plasmids with
or without mutations in the mALAS2 presequence and/or mature enzyme
sequence (Table 2.1, Figure 2.1). Where indicated, the mALAS2 presequence
was mutated at three cysteine residues, C11, C38, and C70, in order to yield
nonfunctional

HRMs

and

thus

eliminate

heme

feedback

inhibition

of

mitochondrial import (18,40). The plasmids were designed such that a single
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bicistronic mRNA, encoding both mALAS2 and the fluorescent protein ZsGreen1,
separated by an internal ribosomal entry site (IRES), would be produced.
Transcriptional expression of mALAS2 and ZsGreen1 was under control of the
constitutively active cytomegalovirus (CMV) promoter (44). Twenty-four hours
post-transfection, wild-type mALAS2 with a wild-type presequence (WT )
expression caused a slight, but statistically significant as defined by Student’s ttest (p<0.05), increase in PPIX accumulation (Figure 2.2A). The K313A mutation
in ALAS2 leads to undetectable enzymatic activity values in vitro (45), and under
ex vivo conditions this also appears to be the case, as no PPIX accumulated in
K313A-expressing cells (K313A ), a result similar to that of the mammalian cells
harboring the pIRES2-ZsGreen1 vector (ZsGreen1) alone (Figure 2.2A). In
Table 2.1. Plasmid constructs used to express murine ALAS2 variants in
mammalian cell lines.
Plasmid Name

Mutations in
mALAS2 Presequence
Mature mALAS2 Sequence
1
pIRES2-ZsGreen1
N/A
N/A1
2
pEF21
-----2
pEF22
---2
V423L,Y428R,P432E,
R433I, G434N, E435Q and
L437K
pEF23
---2
K313A
pEF24
C11S, C38S and C70S
---2
pEF25
C11S, C38S and C70S
V423L,Y428R,P432E,
R433I, G434N, E435Q and
L437K
pEF26
C11S, C38S and C70S
K313A
pEF31
C11S, C38S and C70S
R433K
1
2
N/A, non-applicable; ---, no mutations.
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comparison to WT , the heptavariant mutations in the active site loop alone
(HPVT ) and mutations in the presequence alone (WT) caused a statistically
significant (p<0.05) increase in PPIX production in expressing cells (Figure 2.2A).
The combination of the heptavariant mutations in the active site loop and
mutations in the presequence (HPVT) resulted in variable PPIX production that
was not statistically significant. Somewhat unexpectedly, it was expression of the
mALAS2 variant with a mutated presequence containing the R433K mutation
(R433K) that caused the largest accumulation of PPIX. Mutation of R433 residue
to a lysine in the purified, mature enzyme results in an increase in activity to
twice that of the wild-type enzyme (i.e., a 2-fold increase in the kcat value and a

Figure 2.1. Murine ALAS2 protein schematic indicating mutated amino acid
residues. The green dotted lines represent the relative locations of the three cysteines
in the HRMs of ALAS2. C11 and C38 are in the ALAS2 presequence. K313A, R433K,
and the heptavariant mutations and their respective positions are indicated according to
the amino acid numbering previously described for mature mALAS2 (31,35,36). The
amino acid positions according to the numbering for the precursor enzyme are written
above the diagram.
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1.65 to 1.85-fold enhancement in the specificity constants for glycine and
succinyl-CoA over those of wild type, mature mALAS2)

(31). Similarly, the

increase in PPIX accumulation in HeLa cells expressing the R433K precursor
with a mutated presequence was approximately 2.5-fold compared to the cells
expressing WT and 2-fold in comparison to cells expressing WT (Figure 2.2A).
Because PPIX can be used as a photosensitizing agent for PDT of
cancers, we examined the effect of combining mALAS2-induced PPIX
accumulation with the chemotherapeutic drug paclitaxel, a well-characterized
inhibitor of mitosis (46-48). Only mALAS2 variants with mutated presequences
were used in the drug combination experiments, since those variants presented
the most potential for PPIX accumulation, and thus, subsequent cell death
resulting from light-induced phototoxicity. A dose response curve revealed that
the concentration of paclitaxel that killed 25% of HeLa cells in 48 hours (IC25)
was 10 nM (data not shown), and this concentration was chosen as the desired
concentration for the PDT combination experiments. Paclitaxel had no
statistically significant effect, as defined by Student’s t-tests, on the amount of
accumulated PPIX in the mammalian cells transfected with any of the ALAS2
variants after 48 hours (Figure 2.2B). The largest increase in PPIX fluorescence
was observed with the R433K variant, regardless of whether or not paclitaxel was
included in the culture medium (Figure 2.2B).

Supplementation of cell culture medium with glycine leads to increased
PPIX accumulation in mALAS2-expressing HeLa cells—Given that PPIX is a
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Figure 2.2. Porphyrin accumulation in transiently transfected HeLa cells with
mALAS2 WT- and variant-encoding plasmids. (A) HeLa cells transfected with
mALAS2 variants with and without ( ) mutated presequences analyzed 24 hours after
transfection. (B) HeLa cells transfected with mALAS2 variants with mutated
presequences, in cells cultured in the absence or presence of 10 nM paclitaxel (Pct),
analyzed 48 hours after transfection. Normalized PPIX fluorescence values were
obtained by first dividing the mean PPIX fluorescence by the mean ZsGreen1
fluorescence for each cell population and secondly dividing by the mean PPIX
fluorescence/ZsGreen1 fluorescence ratio of the pIRES2-ZsGreen1-transfected cells.
Each data set represents three separate experiments ± standard deviation (*p<0.05 and
**p<0.01, Student’s t-test) [a.u., arbitrary units].

photosensitizer (49) and the Michaelis-Menten constant (Km) of mALAS2 for
glycine, at 25±4 mM (3,25,34), is significantly higher than its intracellular
concentration of approximately 2.5 mM (50), it is plausible that supplementation
of the cell culture medium with glycine would lead to enhanced synthesis of ALA,
and consequently, PPIX, which in turn might increase the efficacy of PPIXinduced phototoxicity. To examine whether increased glycine concentration
caused enhanced PPIX accumulation, HeLa cells transfected with mALAS2 (wild
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type and variants) were grown in medium with different glycine concentrations
(Figure 2.3A). Samples with culture medium supplemented with 100 μM ALA for
4 hours served as a control for PPIX accumulation independent of glycine
concentration (Figure 2.3B). The concentration and treatment times for ALA were
chosen based on experiments indicating that the extent of PPIX accumulated in
HeLa cells supplemented with 100 μM ALA was similar to that of HeLa cells
expressing R433K, the mALAS2 variant that induces the highest levels of PPIX
accumulation in these cells. HeLa cells expressing WT, HPVT or R433K in
culture medium supplemented for 18 hours with 10 mM or 100 mM glycine
exhibited significant increases in PPIX in comparison to the “no glycine” controls,
with R433K again demonstrating the highest PPIX accumulation (p<0.01) (Figure
2.4A). Supplementing the culture medium with either 10 mM or 100 mM glycine
for cells expressing WT resulted in approximately 4- and 6-fold increases in PPIX
accumulation, respectively, as compared to no glycine supplementation. For cells
expressing R433K, glycine supplementation more than tripled the PPIX
accumulation, representing a fourteen-fold increase over the control HeLa cells
supplemented with glycine. Cells expressing HPVT were also affected by
addition of either 10 mM or 100 mM glycine, increasing the PPIX by 1.4-fold and
2.5-fold, respectively. Glycine elicited no effect on PPIX production in HeLa cells
alone, those treated with 100 μM ALA, or HeLa cells expressing the pIRES2ZsGreen1 vector (Figure 2.3B).
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Figure 2.3. Glycine supplementation of culture medium increases PPIX
accumulation in HeLa cells expressing murine wild-type, HPVT, and R433K
ALAS2. (A) PPIX fluorescence 24 hours after transfection and 18 hours after
supplementing culture medium with 10 mM glycine or 100 mM glycine. Normalized PPIX
fluorescence values were obtained by dividing the mean PPIX fluorescence by the mean
ZsGreen1 fluorescence for each cell population. Mean PPIX fluorescence values are
representative of three separate experiments ± standard deviation (**p<0.01, one-way
ANOVA) [a.u., arbitrary units]. (B) ZsGreen1 fluorescence versus PPIX fluorescence in
HeLa cell populations supplemented with 100 mM glycine as measured by flow
cytometry. In each dot plot, cells in the green-fluorescent range are represented in green
and to the right of the vertical black line, while cells that are not green-fluorescent are in
blue. Cells that are red-fluorescent due to PPIX accumulation are above the horizontal
black line, while cells that are not red-fluorescent are below the horizontal black line. The
percentage of cells in each quadrant is written in the corners of each dot plot. “Control”
refers to non-transfected HeLa cells.

Glycine and deferoxamine increase PPIX accumulation in mALAS2expressing K562 cells—We generated stable K562 human myelogenous
erythroleukemia cell lines expressing mALAS2, expecting that these cells might
accumulate high amounts of PPIX, due to their similarity to undifferentiated
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erythrocytes (51). We expressed only WT and HPVT in order to test if HPVT
could have higher activity in a cell line in which ALAS2 in normally expressed.
Initially, the stable cell lines expressing WT did not show an increase in PPIX
fluorescence as compared to regular K562 cells (Figure 2.4A), and we postulated
that glycine availability was again a limiting factor, as we had observed in HeLa
cells (Figure 2.3). Another possible limitation upon PPIX accumulation could be
a more effective conversion of PPIX into heme in K562 cells, in which case the
inclusion of an iron-specific chelator such as deferoxamine should increase the
PPIX fluorescence by reducing or even preventing this conversion. To address
why the expression of mALAS2 alone did not cause a larger increase in PPIX
and what could limit the ALAS2-induced PPIX accumulation, the culture medium
supplemented with glycine to yield final concentrations of 10 mM or 100 mM
glycine (Figure 2.4A and 2.4C) or deferoxamine mesylate to yield a final
concentration of 100

M deferoxamine mesylate (Figure 2.4B and 2.4D).

Expression of WT in K562 cells did not increase the cellular PPIX fluorescence,
but PPIX fluorescence increased by more than 5– and 10–fold when the culture
medium contained 10 mM glycine and 100 mM glycine, respectively (Figure
2.4A). No significant differences were seen in cells not expressing mALAS2
(Figure 2.4C) or in cells expressing HPVT when treated with 10 mM glycine
(Figure 2.4A). However, in contrast to HeLa cells, when 100 mM glycine was
used, cells expressing HPVT did exhibit an increase in PPIX fluorescence by
approximately 3-fold (Figure 2.4A).
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Deferoxamine is a well-characterized iron-specific bacterial siderophore
with a long history of clinical use in iron chelation therapy. Deferoxamine has the

Figure 2.4. Stable expression of murine ALAS2 variants in K562 cells results in
PPIX accumulation when culture medium is supplemented with either glycine or
deferoxamine. (A) PPIX fluorescence after supplementation of the culture medium with
glycine. (B) PPIX fluorescence after supplementation of the culture medium with
deferoxamine (+D). (C) PPIX fluorescence of K562 cell populations supplemented with
glycine. The blue area represents cells that do not express ZsGreen1, and the green
area represents the population that expresses ZsGreen1. K562 cells that express
ZsGreen1 are not affected by glycine supplementation of the culture medium (upper
plots), while cells that express WT exhibit a significant increase in PPIX fluorescence
when the culture medium is supplemented with glycine (lower plots). (D) PPIX
fluorescence of K562 cell populations grown in culture media containing deferoxamine.
Cell growth in the presence of deferoxamine significantly increases the PPIX
fluorescence in K562 cells expressing WT, but does not affect PPIX fluorescence in cells
expressing only ZsGreen1 or HPVT, as indicated by the number of cells within the red
dotted-line boxes.
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potential to increase PPIX by decreasing the cellular iron concentration, thereby
inhibiting the conversion of PPIX to heme (52,53). Treatment of K562 cells with
deferoxamine for 18 hours caused no change in PPIX fluorescence in cells not
expressing mALAS2 or cells expressing HPVT. Deferoxamine did cause a
significant increase in PPIX in cells expressing WT, in which case the mean PPIX
fluorescence increased from 1.4-fold over cells expressing ZsGreen1, to 2.4-fold
with deferoxamine (Figure 2.4B and 2.4D).

PPIX primarily accumulates and localizes at the plasma membrane in
HeLa cells expressing R433K—To evaluate cellular intactness and accumulated
PPIX distribution in the transfected HeLa cells, we used confocal microscopy to
visualize the fluorescent PPIX in individual HeLa cells (Figure 2.5A) and HeLa
cells transfected with either the pIRES2-ZsGreen1 vector (Figure 2.5B) or pEF31
(harboring R433K) (Figure 2.5C). Transfected cells were grown in medium
supplemented with 100 mM glycine for 18 hours in preparation for imaging. The
outline of intact cells, and thus their morphological integrity, was evident in the
three cases. As expected, green fluorescence was visualized in the transfected
(Figures 2.5B and 2.5C) but not control HeLa cells (Figure 2.5A). In fact, green
fluorescence, arising from the soluble ZsGreen1 green fluorescent protein was
observed evenly distributed throughout the cytoplasm of the HeLa cells
transfected with either pIRES2-ZsGreen1 (Figure 2.5B) or the R433K-expression
plasmid (Figure 2.5C). While the enzyme protoporphyrinogen oxidase catalyzes
PPIX production exclusively within the mitochondrion, PPIX accumulated
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primarily within the plasma membranes of HeLa cells expressing R433K, as
visualized by the characteristic red fluorescence; however, PPIX build-up was
also apparent within the cells (Figure 2.5C). Thus, it appears that much of the

Figure 2.5. Fluorescence microscopy of HeLa cells expressing GFP and the
R433K mALAS2 variant. From left to right for each row, the panels correspond to (1)
brightfield, (2) green fluorescence, (3) red fluorescence, (4) superimposed green and (5)
red fluorescence, and superimposed brightfield, green fluorescence, and red
fluorescence images. (A) HeLa cells grown to 100% confluency in culture medium with
100 mM glycine. (B) HeLa cells transfected with pIRES2-ZsGreen1 and grown in culture
medium to 100% confluency with 100 mM glycine. (C) HeLa cells transfected with
pEF31, which expresses the R433K variant from the CMV promoter in the pIRES2ZsGreen1 vector (Table 2.1), and grown to 100% confluency in culture medium with 100
mM glycine. (D) HeLa cells transfected with pEF31 and grown in culture medium to 80%
confluency with 100 mM glycine. Pictures were obtained 24 hours after transfection and
18 hours after glycine supplementation. ZsGreen1 (green) is present throughout the cell,
while PPIX (red) accumulates at the plasma membrane of cells expressing R433K and
surrounding cells.
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PPIX produced in the mitochondria eventually accumulates in the plasma
membrane, entirely consistent with the fact that PPIX is a relatively lipophilic
molecule. Of note, PPIX accumulated in not only transfected cells, but also in
surrounding cells, indicating that PPIX could leave the transfected cells and be
taken up by nearby cells (Figure 2.5C). It is very likely that, additionally, PPIX
accumulated in organelle membranes within the cell, such as in the
mitochondrion, but since PPIX photobleached within a few seconds under the
conditions utilized here, it was not possible to obtain high-resolution organelle
images with our current microscopic parameters.

ALAS2-induced PPIX accumulation followed by light exposure combined
with paclitaxel treatment causes cell death—Both propidium iodide and DAPI
staining were utilized to assess cell viability after mALAS2-induced PPIX
accumulation, light exposure, and paclitaxel treatment, based on the specific
fluorescence emission of each dye when bound to the DNA of intact cells. Stains
were added to cell samples 48 hours after transfection, and the fluorescence of
DNA-bound propidium iodide and DAPI were measured by flow cytometric
analysis using the respective fluorescence emission maxima of 613 nm and 460
nm. Expression of WT or HPVT did not significantly increase cell death following
light exposure. However, expression of R433K caused a statistically significant
(p<0.05) increase in cell death of up to 30%, as measured both by propidium
iodine (Figure 2.6A) and DAPI (Figure 2.6B) staining, in comparison to
expression of ZsGreen1 alone. Addition of paclitaxel increased cell death in all
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samples, including controls, by 10-25%. HeLa cells expressing R433K and
treated with paclitaxel exhibited the highest percentage of up to 50% cell death
(Figure 2.6A-B). Combination of paclitaxel with mALAS2-induced PPIX
accumulation and light treatments exhibited an additive effect in causing death in
HeLa cells.

Figure 2.6. Light-induced cell death of HeLa cells expressing mALAS2 variants. (A)
Cell death measured by changes in DNA-bound propidium iodide fluorescence. (B) Cell
death measured by changes in DNA-bound DAPI fluorescence. HeLa cells were
transfected with expression plasmids for either wild type (WT) or mALAS2 variants and
treated with 10 nM paclitaxel 4-hour post-transfection. 48 hours after transfection, cells
were stained and analyzed by flow cytometry. Cell death percentage values were
compared to that of the pIRES2-ZsGreen1-transfected cells control. Each data set
represents three separate experiments ± standard deviation (*p<0.05 and **p<0.01,
Student’s t-test).

Supplementation
phototoxicity

and

cell

of

cell

death

culture
in

medium

with

mALAS2-expressing

glycine

enhances

HeLa

cells—The

phototoxicity and subsequent cell death caused by mALAS2-induced PPIX
accumulation, when the culture medium was supplemented with glycine, were
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also investigated in HeLa cells. Cell viability was measured using propidium
iodide (data not shown), DAPI staining, and MTT assays (Figure 2.7) 24 hours
post-transfection, 18 hours after glycine addition, and 4 hours after ALA addition.
Significant cell death was ascribed to those samples that exhibited more cell
death compared to the pIRES2-ZsGreen1-transfected cells with the same glycine
concentration as determined by one-way ANOVA (p<0.05). Transfection of HeLa
cells with the pIRES2-ZsGreen1 plasmid caused a decrease in cell viability by an
average of 30%, which can be attributed to the mild cytotoxicity of the
transfection reagents (54).
Expressing WT, regardless of the glycine concentration in the culture
medium, caused approximately 70% cell death following light exposure, as
measured by DAPI staining (Figure 2.7A-B). In the MTT assays, expression of
WT only caused statistically significant cell death (p<0.05) with supplementation
of 100 mM glycine, in which case only an average of 15% of cells remained
viable (Figure 2.7C). HeLa cells expressing HPVT or R433K did exhibit a glycinedependent increase in cell death when the glycine concentration reached 100
mM as measured by both DAPI staining and MTT assays. When 100mM glycine
was added, cells expressing HPVT decreased from an average of 81% viable to
13% viable, and cells expressing R433K decreased from 58% viable to 25%
viable as measured by MTT assays (Figure 2.7C). ALA treatment did not cause
significant cell death (p>0.05), regardless of glycine concentration, when
measured by either DAPI staining or MTT assays.
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Figure 2.7. Light-induced cell death in murine ALAS2 variants-expressing HeLa
cells cultured in a medium supplemented with glycine. (A) Cell death, as assessed
by DAPI fluorescence, are representative of three separate experiments ± standard
deviation (*p<0.05 and **p<0.01, one-way ANOVA). (B) Cell death in HeLa cell
populations grown in culture medium supplemented with glycine. The percentage of cells
in each quadrant is written in the corners of each dot plot. (C) Cell viability as measured
by metabolism of MTT. Cells were transfected 24 hours before light treatment, and 100
mM glycine was added 18 hours before light treatment. Cell viability percentage values
are normalized to MTT metabolism in healthy, untreated HeLa cells and are
representative of at least three separate experiments ± standard deviation (*p<0.05,
one-way ANOVA). “Control” refers to non-transfected HeLa cells.

Discussion
Photodynamic therapy (PDT) is a widely utilized clinical procedure for
many types of cancer, as well as dermatological conditions such as psoriasis
and schleroderma (55-57). PDT is often initiated by application of the pro-drug 581

aminolevulinic acid (ALA) to the patient in order to photosensitize the tissue to
be treated (49). ALA-PDT is very effective, has minimal side effects and is being
tested in numerous clinical trials on a wide-spectrum of cancers (49). There are,
however, some limitations to ALA-PDT and other PDTs that provide
opportunities for improvement. For example, there is no specific mechanism that
targets PPIX to tumor cells after ALA has been applied, other than a slightly
preferential uptake of photosensitizers by hyperproliferating cells

(58).

Consequently, normal tissue can be damaged from the procedure due to
unintentional exposure to light resulting in pain, and conversely, not all
hyperproliferating cells necessarily become highly sensitized (55,59) . In an
attempt to restrict photosensitivity by biological, rather than just chemical or
physical means, an adenovirus expressing human ALAS2 with mutated HRMs
was generated and H1299 lung carcinoma cells were successfully infected (40).
The adenovirus-infected H1299 cells accumulated more PPIX and became more
photosensitive than cells supplied with ALA in their media, indicating that
delivery of ALAS to tumors could potentially be a useful tool for PDT not only for
better targeting, but also for greater photosensitivity (40). However, the cell
death was only 26% even in the presence of deferoxamine (40), leading us to
postulate that one or more highly active variants of mALAS2 (31,35) would
increase PPIX accumulation, phototoxicity, and targeted cell death sufficiently to
make the approach more clinically attractive.
To explore the ability of mALAS2 variants to cause accumulation of PPIX
in mammalian cells, we transfected cells, of both erythroid and non-erythroid
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lineages, with murine ALAS2-expressing plasmids, and quantified the PPIX
fluorescence using FACS analysis. In HeLa cells, we transfected plasmids
encoding mALAS2 both with and without mutated presequences and with or
without mutations in the mature enzyme sequence (Table 2.1, Figure 2.1). As
with many mitochondrial proteins, ALAS2 is synthesized in the cytosol and
contains a sequence at its N-terminus that targets ALAS2 for mitochondrial
import after its synthesis (18). Within the N-terminus of the ALAS2 precursor,
there are three HRMs as recognized by adjacent cysteine-proline residues that
have the potential to bind heme. The HRMs located within the presequence of
ALAS2 (C11 and C38) have been shown to bind heme (24) and subsequently
inhibit the mitochondrial import of ALAS2 (18). Our experiments support the
existing data that the cysteines in the HRMs bind heme, and that mutation of
these HRMs relieve the inhibition of mitochondrial import, thus resulting in
increased mature, functional ALAS2, as reflected by increased cellular
concentrations of PPIX when the HRMs are mutated (Figure 2.2A). In our study,
when the HRMs in the presequences of the mALAS2 constructs were mutated to
relieve heme inhibition on mitochondrial import, there were significant increases
in PPIX accumulation in HeLa cells expressing WT, HPVT, and R433K (Figure
2.2A-B).
We tested several mALAS2 variants, covering a range of in vitro activity
from undetectable to higher than wild-type, for capacity to stimulate PPIX
accumulation (31,35,36,60). Transfection of HeLa cells with the negative control
plasmid harboring K313A

resulted in no PPIX increase, as expected (Figure
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2.2A). The mutation of K313 leads to undetectable enzymatic activity in vitro,
attributable to the role of K313 in formation of a Schiff-base linkage with the PLP
cofactor (36), and its additional function as a general base catalyst during the
ALAS-catalyzed reaction (3,28,36,61). In preliminary studies with HeLa cells, it
was observed that expression of HPVT , which has seven mutations in its active
site loop, yielded significantly more accumulated PPIX than expression of the
pIRES2-ZsGreen1 vector control plasmid. HPVT was chosen for this study as
the seven mutations of non-conserved residues in the active site loop resulted in
the most active recombinant protein isolated from a variant library at 20°C (35).
Lendrihas et al. (35) hypothesized that these mutations in the active site loop,
which increase both hydrophilicity and basicity, destabilize the loop by both
increasing solubility and eliminating hydrophobic and electrostatic interactions
that would typically act to stabilize the loop in its closed confirmation. However,
the hyperactivity of HPVT was temperature-dependent; while at a temperature
of 20 C these seven mutations increased the kcat value of the recombinant,
mature enzyme to more than 10 times of that of the WT enzyme, at 35 C the kcat
values were nearly the same (35). While the levels of accumulated PPIX in HeLa
cells expressing HPVT were significantly affected by supplementation with
glycine (p<0.01), those in K562 cells expressing HPVT were only modestly
increased when the medium was supplemented with 100 mM glycine. However,
the HPVT-promoted PPIX concentration enrichments were much lower than
those in cells expressing WT or R433K (Figures 2.3 and 2.4). The relatively low
levels of PPIX associated with HPVT expression are presumably due to the
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temperature-dependent activity profile of this particular mALAS2 variant. HPVT
was isolated from a library of mALAS2 variants engineered to possess greater
enzymatic activity than wild type mALAS2 by targeting the active site loop to
acquire different degrees of mobility (35). Since the mutations in HPVT
destabilized the active site loop and altered the protein conformation (35), it
would not be surprising if this variant had a decreased cellular stability.
Additionally, the HPVT mutations may affect protein-protein interactions,
specifically the ability of mALAS2 to interact with a known binding partner,
succinyl-CoA synthetase (62).
The simple addition of the non-toxic substrate glycine to the cell media
increased PPIX production by WT, HPVT, and R433K significantly. When the
culture medium was supplemented to a final concentration of 10 mM or 100 mM
glycine, PPIX production in HeLa cells expressing WT was increased by more
than 4- and 6-fold for each concentration, respectively (Figure 2.3). In K562 cells
expressing WT, the effect was even larger, as PPIX increased by more than 5and 10-fold for 10 mM and 100 mM glycine, respectively (Figure 2.4A and 2.4C).
The slightly higher increases in PPIX concentrations in the K562 cells when
treated with glycine could be due to the stable expression of ALAS2 versus the
transient transfection used in the HeLa cells. However, the ability of the K562
cells to tolerate higher expression of WT and production of PPIX, in comparison
to HeLa cells, might also be attributable to their erythroid lineage. K562 cells are
of the erythroleukemic cell type, and bear some proteomic resemblance to
undifferentiated erythrocytes (51,63) and express endogenous ALAS2. Thus
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while expressing ALAS2 in HeLa cells introduces an enzyme that does not
normally exist in epithelial cells, K562 cells may adapt more easily to the
expression and up-regulation of the heme biosynthetic pathway. It seems likely
that the capacity of mALAS2 to accumulate PPIX will be found to vary in other
mammalian cell types as well.
Supplementing the culture medium of K562 cells expressing WT with 100
μM deferoxamine, an iron-chelator previously shown to increase the amount of
PPIX in ALAS adenovirus-infected H1299 cells (40), resulted in increase in the
mean PPIX fluorescence per cell (Figure 2.4B and 2.4D), but it was much less
than with glycine supplementation. However, the modest increase was similar to
what Gagnebin et al. (40) observed in the ALAS adenovirus-infected cells,
suggesting the much larger increases reported here with R433K and glycine
supplementation

represent

substantial

advancements

in

our

ability

to

overproduce PPIX in mammalian cells. R433K is only twice as active as WT in
vitro, and it is reasonable to believe that significantly more active variants could
be readily produced via directed evolution, and that these variants would facilitate
even greater levels of PPIX accumulation, perhaps to the point of expanding the
clinical applicability of PPIX-based PDT.
The HeLa cells that accumulated the highest amount of PPIX were those
expressing R433K. The R433K mutation was analyzed in 1998 by Tan et al. (31)
in a study that identified the nearby R439 as being a conserved residue in many
α-family PLP-dependent enzymes, as well as being involved in binding of the
amino acid substrate during catalysis (31). In that study, the kinetic parameters
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were defined for R439L, R439K, R433L, and R433K. Although not the primary
focus of the article, the kinetic parameters for R433L were found to be
comparable to those of the wild-type at 37°C, while for R433K the kcat was
increased by two-fold, with no effect on the Michaelis constants, resulting in a
doubling of catalytic efficiency for both substrates (31). In the results detailed
here, expression of R433K in HeLa cells produced a 2- to 3-fold increase in PPIX
in comparison to WT, and a 4- to 6-fold increase in PPIX fluorescence in
comparison to cells transfected with the pIRES2-ZsGreen1 vector control or
HeLa cells alone (Figure 2.2). When the culture medium was supplemented with
glycine, PPIX accumulation increased by 13- to 15-fold in comparison to cells
transfected with the pIRES2-ZsGreen1 vector control or HeLa cells alone, and
represented the conditions for the highest cellular PPIX accumulation. Given that
within these samples there were cells fluorescing with PPIX that were not
ZsGreen1-expressing (Figure 2.3B), some of the PPIX produced in the R433Kand WT-expressing HeLa cells appears to have been transported out of the cells
into the culture medium, where it was then taken up by non-transfected cells.
These populations of red-fluorescing cells were comparable to those cells in
culture medium supplemented with ALA (Figure 2.3B). This is a very important
finding in terms of the potential of these constructs for photodynamic therapy, as
it indicates that the PPIX produced within a delivery cell could be transported into
surrounding diseased tissue and accumulate to clinically relevant levels.
The subcellular distribution of a photosensitizing agent might have
important consequences in regards to PDT efficacy (64).
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Fluorescence

microscopy was successfully utilized to visualize PPIX accumulation in R433K
expressing HeLa cells. Due to the extremely short time (a few seconds) it took
for PPIX to photobleach, the resolution could not be optimized for visibility of
individual organelles such as mitochondria and nuclei. However, it was possible
to observe that PPIX had accumulated in the plasma membranes of the R433K
expressing cells; and this fluorescence was not seen in the pIRES2-ZsGreen1
vector-expressing cells (Figure 2.5). It also appears that PPIX can exit the
transfected cells, potentially via ABC transporters such as ABCB6 (65,66) or
ABCG2 (67,68), and enter surrounding cells. Presumably, the lipophilic PPIX
accumulated in the organelle membranes as well, but direct microscopic
confirmation of PPIX accrual in organelle membranes awaits approaches
resulting in better resolution than we were able to achieve here.
In order to study the photosensitivity of cells that accumulated PPIX
(caused by expression of WT, HPVT, and R433K), we performed light treatments
using an incandescent lamp, which emits light in the visible and infrared spectral
regions (400-1000 nm). The cells were exposed for 10 minutes before FACS
analysis of PPIX and cell death. Expression of the ZsGreen1 protein alone
caused a toxicity that was independent of light treatment, and thus significant cell
death was measured against the pIRES2-ZsGreen1 vector-transfected cells
(p<0.05) as opposed to HeLa cells alone (Figure 2.7). Regardless of glycine
concentration, the expression of WT led to a significant increase in cell death by
1.4- to 2-fold. R433K and HPVT, when the culture medium was supplemented
with 100 mM glycine, also caused significant increases in cell death by 2.1- and
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1.6-fold, respectively. With no or 10 mM glycine supplementation the error was
too high for any of the increases to be significant, although there was a trend
towards increased cell death. For WT and R433K, increased PPIX accumulation
correlates with increased cell death after light treatment. In spite of the more
modest increases in PPIX accumulation, light-induced death also occurred in
HPVT-expressing cells. This finding led us to suggest that toxicity inherent to the
overproduced HPVT protein is the other contributing factor to cell death.
Although purified recombinant, mature HPVT is more active than WT at 37°C
(with an enhancement of approximately 1.5 in the kcat value at 37°C vs. a 15.5fold increased kcat at 20 °C) (35), when expressed in mammalian cells, HPVT is
not as active as WT, as determined by PPIX fluorescence. Since expression of
HPVT paired with glycine supplementation caused significant cell death (Figure
2.7), the potential role of another toxic heme pathway intermediate, such as the
pro-oxidant ALA (69-72), in causing cell death, is plausible. However, at present,
different levels of protein expression [Quantification of ALAS2 and variant protein
levels was not feasible due to the unavailability of a functional ALAS2 antibody.]
and distinct modulation of the enzymatic activity between ALAS2 and variants
cannot be ruled out as possibilities. Treatment with 100 μM ALA, a positive
control for PPIX accumulation, caused a similar cell death after light exposure to
expression of the ZsGreen1 protein alone. In summary, the highest cell death
was seen in light-treated HeLa cells expressing ZsGreen1 and either WT, HPVT,
or R433K, in culture medium supplemented with 100 mM glycine. The total cell
death was observed to be as high as 90% in the cells expressing both ZsGreen1
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and R433K. This represents a substantial improvement upon the 26% cell death
reported previously (40), and indicates that this approach, if carefully developed,
may eventually find some clinical utility.
Because ALAS2, especially highly stable and active variants of ALAS2,
would be useful in the development of multiplex cancer treatments involving PDT,
we experimented with combination PDT and drug treatments of HeLa cells.
Paclitaxel (Taxol) is currently approved in the United States for the treatment of
AIDS-related Kaposi sarcoma (73), breast cancer (74), non-small lung cell lung
cancer (75), and ovarian cancer (76). Paclitaxel induces apoptosis in cancer cells
by binding to tubulin and inhibiting the disassembly of microtubules, thereby
resulting in the inhibition of cell division (46,77). As expected, paclitaxel did not
affect PPIX accumulation, as indicated by the similar mean PPIX fluorescence
values between untreated and paclitaxel-treated cells (Figure 2.2B). However,
paclitaxel had an additive effect to PDT and increased cell death in all samples
by 10-25%. HeLa cells expressing R433K treated with paclitaxel exhibited the
highest percentage of cell death (Figure 2.6A-B). Ever since PDT was first shown
to be able to elicit an immune response (78), many recent advances in PDT are
aiming toward creating PDT-generated cancer vaccines (79). Using highly active
and stable ALAS2 variants as part of a vaccine strategy for photosensitization
may be useful for this vaccine approach. Further experiments, both in cell culture
and live animals, are necessary to test for potential immune response stimulated
by ALAS2-PDT.
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In this study, we have shown that transfecting mammalian cells, of both
erythroid and non-erythroid lineages, with mALAS2 variants, is an effective way
to stimulate cellular PPIX accumulation. Furthermore, supplementing the culture
medium with glycine vastly increases the intracellular PPIX levels when cells
express either WT or R433K. These data offer new ways to accumulate high
levels of the photosensitizer PPIX in cancer cells for more targetable and efficient
PDT. Human ALAS2 variants with higher than normal activity are now known to
occur in nature, and are associated with a form of erythropoietic protoporphyria
known as X-linked dominant protoporphyria, which is characterized by a 24-fold
increase in erythrocyte PPIX concentrations (39). It would be appropriate if these
variants were eventually utilized in PDT, and could thereby allow clinicians to
exploit one disease to treat or cure others.
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CHAPTER 3: MUTATIONS IN THE C-TERMINUS OF HUMAN ERYTHROID
5-AMINOLEVULINATE SYNTHASE ASSOCIATED WITH X-LINKED
ERYTHROPOIETIC PROTOPORPHYRIA ALTER ENZYME STRUCTURE,
KINETICS, AND EX VIVO ACTIVITY
Abstract
Five different frameshift mutations in the final coding exon of the human
erythroid ALAS (hALAS2) gene are associated with X-linked erythropoietic
protoporphyria (XLEPP), a disease phenotypically characterized by elevated
levels or protoporphyrin IX (PPIX) and zinc protoporphyrin in erythroblasts. This
is apparently due to enhanced cellular ALAS2 activity, but the biochemical
relationship between these C-terminal mutations and increased ALAS2 activity is
not well understood. Mutations in the hALAS2 C-terminus associated with
XLEPP were characterized using purified recombinant hALAS2 to compare
kinetic and structural parameters and studied ex vivo in HeLa and K562 cells.
Two XLEPP variants, delAGTG and Q548X, when compared to wild-type
hALAS2, exhibited higher catalytic constants and affinity for succinyl-CoA,
increased transition temperatures, and caused porphyrin accumulation in HeLa
and K562 cells. Another XLEPP mutation, delAT, had an increased transition
temperature and caused porphyrin accumulation in mammalian cells, but
exhibited a reduced catalytic constant at 37°C in comparison to wild-type
hALAS2. The XLEPP variants were more structurally responsive upon binding of
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succinyl-CoA, and adopted distinct features in tertiary and PLP-cofactor binding
site structure. These results imply that the C-terminus of hALAS2 is important for
regulating its structural integrity, which affects kinetic activity and stability.

Introduction
5-Aminolevulinate synthase (ALAS) is a homodimeric, pyridoxal-5’phosphate (PLP)-dependent enzyme that catalyzes the first and key regulatory
step of heme biosynthesis in non-plant eukaryotes, as well as the α-subclass of
purple bacteria (1-3). The reaction involves the condensation of glycine and
succinyl-CoA to produce 5-aminolevulinate (ALA), CoA, and carbon dioxide (1).
Animal genomes encode two highly conserved but differentially expressed ALAS
genes, a housekeeping gene (ALAS1) and an erythroid-specific gene (ALAS2)
(4). In humans, mutations in ALAS2 can result in two very different diseases, Xlinked sideroblastic anemia (XLSA) and X-linked erythropoietic protoporphyria
(XLEPP).
In XLSA, the mutation of ALAS2 leads to a decrease in activity, and thus a
decrease in porphyrin synthesis, resulting in iron accumulation in the
mitochondria of erythroblasts and anemia (5-8). ALAS2 mutations associated
with XLSA have been identified in exons 4-11 of the ALAS2 gene, which encode
the highly conserved catalytic core region of the enzyme (9). The discovery of
XLSA began with reports that ALAS activity in the bone marrow of inherited
sideroblastic anemia patients is decreased, indicating that impairment of heme
biosynthesis may induce the onset of certain sideroblastic anemias (10-12).
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Shortly after ALAS2 was mapped to region Xp11.21 of the X chromosome
(13,14), the first sideroblastic anemia patient with a mutation in ALAS2 was
reported (15), supporting the theory that ALAS2 deficiency results in both a
decreased supply of heme for hemoglobin and iron accumulation in the
mitochondria of erythroblasts. Since the identification of the first XLSA patient, at
least 61 different mutations in ALAS2 in patients with XLSA have been identified
(9,16-18). In more than 50% of XLSA patients, the mutation in ALAS2 decreases
the affinity of ALAS2 for its cofactor PLP, and these patients are responsive to
treatment with oral pyridoxine, which increases the amount of available PLP
(9,17). In patients not responsive to pyridoxine, the ALAS2 mutations can create
a premature stop codon or alter enzyme stability, leading to a decrease in protein
level (9). ALAS2 protein levels can also be decreased as a result of mutations in
the ALAS2 promoter, which decrease the transcription of ALAS2 resulting in
XLSA (19). It is clear that a single amino acid change in a variety of locations in
ALAS2 can decrease its function in vivo, and the mechanism by which the
activity is reduced can be due to a decreased affinity for its PLP cofactor, affinity
for its substrate/s, stability, and/or transcription.
Yet, in 2008, C-terminal mutations in patients that lead to an increase in
ALAS2 function were discovered (20), raising the question of how certain
mutations in the C-terminus of ALAS2 cause decreased function, while other
mutations in the same region result in an increased function. In XLEPP, ALAS2
mutations in the C-terminal region lead to increased activity, and thus an
accumulation of the heme precursor, protoporphyrin IX (PPIX), as well as zinc106

protoporphyrin (20). In contrast to XLSA, all mutations known associated with
XLEPP are located in the final exon, exon 11, which encodes the far C-terminus
(20-22) (Table 3.1). The final 33 amino acids of ALAS2 are highly conserved and
yet have diverged from the ALAS1 isoform, suggesting that these residues may
have an erythroid-specific function (20). Additionally, the C-terminal amino acids
are conserved in higher eukaryotes but not present in prokaryotes, and deleting
the final 33 amino acids of recombinant hALAS2 results in an increase in the
catalytic activity (21). Given that mutations at the C-terminus can result in either a
decrease (9,16) or increase (20,22,23) in the function of hALAS2, the
mechanisms by which the C-terminus of hALAS2 can determine its activity
and/or stability are of particular interest.

Table 3.1. C-terminal amino acid sequences resulting from XLEPP mutations.
Genetic
mutation

c.1699-1700

Protein
name
Wild-type
hALAS2
DelAT
(M567E)

hALAS2 sequence

542

AVGLPLQDVSVAACNFCRRPVHFELMSEWERSYFGNMGPQYVTTYA

542

AVGLPLQDVSVAACNFCRRPVHFELE

c.1706-1709

DelAGTG

542

AVGLPLQDVSVAACNFCRRPVHFELMSGNVPTSGTWGPSMSPPMPEKPAA

c.1642C>T

Q548X

542

AVGLPLQ

Here we characterize the kinetics, thermostability, and structure of the
XLEPP variants by evaluating ex vivo activity in HeLa and K562 cells expressing
hALAS2 and XLEPP variants, and using purified recombinant hALAS2 for kinetic
analyses, acrylamide fluorescence quenching, and CD spectroscopy. We
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demonstrate that the C-terminus of hALAS2 is important not only for controlling
its enzymatic activity, but also for maintaining structural integrity.

Materials and Methods
Reagents—Aprotinin,

pepstatin,

leupeptin,

PMSF,

ampicillin,

β-

mercaptoethanol, pyridoxal 5’-phosphate, succinyl-CoA, thiamine pyrophosphate,
and NAD+ were obtained from Sigma-Aldrich Chemical Company. Glucose,
glycerol, acetic acid, methanol, glycine, disodium hydrogen orthophosphate,
sodium dihydrogen orthophosphate, EDTA, MOPS, tryptone, yeast extract,
sodium chloride, tricine, ammonium sulfate, and potassium hydroxide were
purchased from Fisher Scientific. Centricon concentrators were from Millipore.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis reagents and Phusion
DNA Polymerase were acquired from Thermo Scientific. 5-Aminolevulinic acid
hydrochloride was purchased from Acros Organics. BmtI, SalI, BlpI, and BamHI
restriction

enzymes

were

obtained

from

New

England

BioLabs,

Inc.

Oligonucleotides were synthesized by Integrated DNA Technologies. T4 DNA
ligase and ligase buffer were obtained from Thermo Scientific Fermentas and a
bicinchoninic acid protein determination kit was purchased from Thermo
Scientific Pierce.

Plasmids for mammalian expression and protein purification—The following
mutations: c. 1699-1700 AT deletion (delAT, which results in a frame-shift
mutation leading to a truncated ALAS2 protein with a glutamate (E567) as the C108

terminal amino acid (20) and c.1705-1708 AGTG deletion (delAGTG, which
results in the E569G mutation and a 23 amino acid, non-related ALAS Cterminus (20) were introduced into the cDNA of hALAS2 using the QuikChange
method (Stratagene), and confirmed by DNA sequencing. The plasmids
encoding the wild-type hALAS2, delAT, delAGTG, and Q548X sequences were
pSD1, pSD2, pSD3, and pQ548X, respectively. The cDNAs for these proteins
were under the control of the Escherichia coli alkaline phosphatase promoter
(24). For expression plasmids used in the transfection of mammalian cells, the
wild-type precursor hALAS2 cDNA (GenBank: X56352.1) was individually
subcloned into the multiple cloning site of the pIRES2-ZsGreen1 vector
(purchased from Clontech Laboratories, Inc. Mountain View, CA) using the BmtI
and BamHI restriction sites. The digested hALAS2-encoding fragment was
ligated into the digested pIRES2-ZsGreen1 vector using T4 DNA ligase in ligase
buffer at 16°C. Electrocompetent BL21(DE3) cells were transformed by
electroporation with the ligated plasmid DNA and selected by spreading the
transformed cells on LB agar medium containing 10 µg/mL kanamycin sulfate.
Plasmid DNA was purified from a single colony using a QiaPrep Spin Miniprep kit
(Qiagen Inc.), and the sequence of the cloned DNA was verified by Genewiz, Inc.
in New Brunswick, NJ. The resulting plasmid was named pEF27. For the
mammalian expression plasmids encoding the precursor XLEPP variants, the
cDNAs encoding the mutated hALAS2 C-termini were retrieved from pSD2 and
pSD3 and subcloned into pEF27 using the BlpI and BamHI restriction sites. The
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resulting plasmids were named pEF28 and pEF29, encoding delAT and
delAGTG, respectively.
In order to purify hALAS2 and the XLEPP variant proteins using nickel affinity
chromatography, we added six histidine codons to the cDNA sequence encoding
the mature hALAS2 N-terminus. The mature wild-type hALAS2 was amplified
from pSD1 using the oligonucleotides hALAS22 (5’- CGT GTC GAC GAT GCA
CCA TCA CCA CCA TCA CGG GAA GAG CAA GAT TGT GCA GAA G-3’) and
r-hALAS23 (5’-AAG TGG TAA AGA TGA AGC CTG CAG CAT- 3’) as forward
and reverse primers, respectively.

The SalI site and the codons for the six

histidines are indicated in italics and bold, respectively, in the sequence for the
hALAS22 primer (above). The r-hALAS23 reverse primer was designed to anneal
to the DNA coding strand, 531 bp downstream of the BlpI site. The generated
PCR product (1040bp) was digested with SalI and BlpI to yield a 505bp-DNA
fragment that was subsequently subcloned into the previously digested pSD1,
pSD2, pSD3, and pQ548X vectors using T4 DNA ligase in ligase buffer (Thermo
Scientific Fermentas) at 16oC. Electrocompetent BL21(DE3) cells were
transformed by electroporation with the ligated plasmids and selected by
spreading the transformed cells on LB agar medium containing 50 g/mL
ampicillin. Plasmid DNA was purified from a single colony using a QiaPrep Spin
Miniprep kit (Qiagen Inc.). The N-terminal ALAS- and histidine-encoding
sequences were verified by DNA sequencing using the primer r-hALAS17 (5’CTG GTC ATA ACT GAA GAC-3’), which anneals complementarily to the DNA
coding strand and 208 bp downstream of the initiation and histidine codons
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introduced in the sequences for the mature hALAS2 and XLEPP variants. The
resulting plasmids, pEF40, pEF41, and pEF42, were used for the expression of
histidine-tagged wild-type hALAS2, delAT, and delAGTG, respectively.

Cell culture—K562 cells were maintained in RPMI-1640 culture medium
(Mediatech, Inc.), with 10% FBS (Thermo Scientific™ HyClone™), gentamicin
(Mediatech, Inc., 50

g/mL), penicillin (Mediatech, Inc., 60 μg/mL) and

streptomycin (Mediatech, Inc., 100 g/mL) at 37°C in a humidified incubator with
5% CO2. HeLa cells were maintained in DMEM with 4.5 g/L glucose, L-glutamine,
and sodium pyruvate (Mediatech, Inc.), with 10% FBS, gentamicin (50 μg/mL),
penicillin (60 μg/mL) and streptomycin (100 µg/mL) at 37°C in a humidified
incubator with 5% CO2.

Transient transfection of HeLa cells—On the day prior to transfection,
HeLa cells were trypsinized and counted. Approximately 2 x 10 4 cells were
seeded into each well of a 24-well plate in 0.5 mL of DMEM. Cell density was
~30-50% confluent on the day of transfection. For each transfection, 250 ng of
DNA was diluted into 100 μL of DMEM without serum. One μL of
Lipofectamine™ LTX was added into the diluted DNA solution, mixed gently and
incubated for 30-45 minutes at room temperature to form DNA-Lipofectamine™
LTX complexes. The DNA-Lipofectamine™ LTX complexes were added
dropwise to each well containing cells and mixed gently by manually rocking the
plate back and forth for a few seconds. After 4 hours of incubation with the DNA111

Lipofectamine LTX complexes, the medium was aspirated out of each well and
fresh DMEM with 10% FBS, gentamicin (50

g/mL), penicillin (60 μg/mL) and

streptomycin (100 g/mL) was added to each well of cells. Cells were incubated
at 37°C in a CO2 incubator for 24 hours post-transfection before assaying. For
cells treated with glycine, glycine dissolved in DMEM (1M) was added to the
culture medium 4 hours post-transfection.

Transient transfection of K562 human erythroleukemia cells—K562 cells
were transfected with Lipofectamine™ LTX and PLUS™ Reagent, purchased
from Invitrogen (San Jose, CA), according to the supplier’s optimized protocol for
K562 cells. On the day of transfection, a hemocytometer and trypan blue staining
were used to count the cells and determine culture density and viability. In a 6well plate, K562 cells (5 x 105 cells per well) were seeded in a 6-well plate at a
volume of 2 mL of RPMI-1640 growth medium with 10% FBS 30 minutes prior to
transfection. For each transfection, 2.5 μg of DNA was added into 500 μL of
RPMI medium without serum. 2.5 μL of PLUS™ reagent (at a 1:1 ratio to DNA)
was then added directly to the diluted DNA. After gentle mixing and a 10 minute
incubation at room temperature, 10 μL of Lipofectamine™ LTX was added into
the diluted DNA solution, mixed gently and incubated for 35 minutes at room
temperature

to

form

DNA-Lipofectamine™

LTX

complexes.

The

DNA-

Lipofectamine™ LTX complexes were added dropwise to each well containing
cells and mixed gently by manually rocking the plate back and forth. Cells were
incubated at 37°C in a CO2 incubator for 24 hours post-transfection before
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assaying. For cells treated with glycine, glycine dissolved in RPMI (1 M) was
added to the culture medium 4 hours post-transfection.

Preparation of cells for FACS and quantitation of PPIX—HeLa and K562
cells were washed, scraped and resuspended in PBS (80 mM disodium
hydrogen orthophosphate, 20 mM sodium dihydrogen orthophosphate, 100 mM
sodium chloride, pH 7.5) before pipetting into BD Falcon tubes with cell strainer
caps. Preparation of cells for FACS was done under very low light conditions (1-2
Lux as measured by a Pyle PLMT68 light meter) in order to minimize
phototoxicity caused by PPIX accumulation. FACS analyses were performed
using a BD LSR II Analyzer (Becton, Dickinson, and Company) and FACSDiva
Version 6.1.3 software. ZsGreen1 emission was measured between 515 nm and
545 nm (530/30BP filter) when cells were excited using the 488 nm laser. In
order to eliminate any background red fluorescence, the 633 nm-red laser was
blocked during the collection of the PPIX emission data. PPIX emission was
determined in the 619 nm and 641 nm range (630/22BP filter) when cells were
excited with the 405 nm laser. Forward-scatter (FSC) versus side-scatter (SSC)
dot plots were used to gate the whole cells and thus remove the contribution of
the cell debris from the population being examined. A minimum of 10,000 of the
gated whole cells were then depicted in dot plots of SSC versus ZsGreen1
fluorescence, and the “green-fluorescent population” gate was defined based on
untransfected HeLa cells as negative controls. Dot plots of SSC versus PPIX
fluorescence were used to define the PPIX-accumulating cells for both the
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“green-fluorescent” and the “non-green fluorescent” populations. The PPIX gating
was based on the negative control for PPIX, the pIRES2-ZsGreen1 vectorexpressing cells. Normalized PPIX fluorescence values were obtained by dividing
the mean PPIX fluorescence by the mean ZsGreen1 fluorescence for each cell
population.

Protein purification—Similarly to methods previously described (24),
recombinant human ALAS2 and the XLEPP variants were purified from
BL21(DE3) E. coli cells containing the overexpressed protein. BL21(DE3) cells
harboring the expression plasmids for histidine-tagged hALAS2 were grown in
two 125 mL flasks with 50 mL of LB medium containing 100 g/mL ampicillin at
37 C for 8 hours. In each of eight 2 L flasks, 10 mL of bacterial culture was
added to MOPS medium containing 100 g/mL ampicillin for a total volume of 1 L
per flask. The bacterial cultures were grown for 16 hours at 37 C. The cells were
then harvested by centrifugation and stored at -20 C until the day of purification.
All purification procedures were carried out at 4 C as described previously
(25) with minor changes. For proteins purified for activity assays, the cell pellet
was resuspended in 30-40 mL of resuspension buffer (20 mM tricine, pH 8.0
containing 5 mM β-mercaptoethanol, 20 µM PLP, 10% glycerol, and 0.2% Triton
X-100). The following protease inhibitors were also added in all buffers just
before usage: aprotinin, leupeptin, and pepstatin at 1 µg/mL, and PMSF at 10
µg/mL. Following resuspension, the cells were homogenized and lysed by
passing the cells twice through a French press at 10,000 psi. Cell debris was
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removed by ultracentrifugation in a swinging bucket rotor at 104,000 x g for 1
hour. The supernatant containing the protein was then loaded onto an affinity
chromatography column (1.5 x 10cm) packed with HisPur

Ni-NTA resin

(Thermo Fisher Scientific Inc.) previously equilibrated with an “equilibration
buffer” (20 mM tricine, pH 8, containing 20 µM PLP, and 10% glycerol,). The
resin was subsequently washed with 100 mL of buffer A (20 mM tricine, pH 8,
containing 5 mM β-mercaptoethanol, 20 µM PLP, and 10% glycerol), 50 mL of
buffer A, pH 8, with 0.5 M NaCl, 50 mL of a 25 mM imidazole buffer (i.e., 25 mM
imidazole, pH 7.2, containing 5 mM β-mercaptoethanol, 20 µM PLP, and 10%
glycerol), and finally 50 mL of a 50 mM imidazole buffer (i.e., 50 mM imidazole,
pH 7.2, containing 5 mM β-mercaptoethanol, 20 µM PLP, and 10% glycerol).
The protein (either hALAS2 or XLEPP variants) was eluted with 50 mL of a 100
mM imidazole buffer (i.e., 100 mM imidazole, pH 7.5, containing 5 mM βmercaptoethanol, 20 µM PLP, and 10% glycerol). The eluted protein was
immediately concentrated in protein concentrators with a 20,000 molecular
weight cutoff (Thermo Scientific™ Pierce™). During concentration, the buffer
was gradually exchanged to 20 mM tricine buffer, pH 8, containing 20 µM PLP,
and 10% glycerol.
For the purification of proteins used in structural studies, glycerol and free
PLP was eliminated from the buffers. Briefly, the cell pellet was resuspended in
30-40 mL of 20mM sodium phosphate, pH 8.0, containing 300 mM sodium
chloride, 20 µM PLP, and 0.2% Triton X-100. The supernatant containing the
protein was then loaded onto an affinity chromatography column (1.5 x 10cm)
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packed with HisPur

Ni-NTA resin previously equilibrated with a phosphate

equilibration buffer (20 mM sodium phosphate, pH 7.4, 300 mM sodium chloride,
and 10 mM imidazole). The resin was first washed with phosphate equilibration
buffer, followed by washes with increasing imidazole concentrations of 25 mM
and 50 mM. The protein was eluted with 50 mL of a 150 mM imidazole buffer
(i.e., 20 mM sodium phosphate, pH 7.4, containing 300 mM sodium chloride, 150
mM imidazole). The eluted protein was immediately concentrated and gradually
exchanged with 20 mM phosphate buffer, pH 8.
Purity of the protein was assessed by SDS-PAGE. Protein concentration
was determined by the bicinchoninic acid (BCA) assay and bovine serum
albumin as the standard. Protein concentrations are reported on the basis of
subunit molecular masses of 57.3 kDa, 55.0 kDa, and 57.3 kDa, for the wild-type
hALAS2, delAT, and delAGTG variants, respectively, calculated using the amino
acid sequences and ProtPram (26).

Spectrophotometric determination of ALAS activity—ALAS steady-state
activity was determined at 37 C using a continuous coupled enzyme assay on a
Shimadzu UV2100 UV/Vis spectrophotometer as described previously for wildtype ALAS (27). The ALAS steady-state kinetic parameters of wild-type hALAS2
and delAT activities were also determined at 30 C.

Thermostability Assays—ALAS2 samples were placed in a thermocycler
and heated to the desired temperature for 3 minutes, after which the sample was
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cooled to 37°C and used in the ALAS activity assay as described above. All
temperatures for each enzyme variant were performed in triplicate.

Acrylamide Fluorescence Quenching—Fluorescence emission spectra
were collected on a Shimadzu RE-5301 PC spectrofluorophotometer using an
excitation wavelength of 295 nm and protein concentrations of 2 μM in 20 mM
phosphate buffer, pH 8.0. Blank fluorescence spectra were collected from
samples containing all components except enzyme immediately prior to the
measurement of samples containing enzyme and were subtracted from the
spectra of samples containing enzyme. Acrylamide, made just prior to running
the experiments as a 2 M stock, was added to yield final volumes in 100 µM
increments, and the spectra were recorded after each addition. To account for a
significant dilution of the enzyme concentration as acrylamide was added to a
final concentration of 1 M, emission intensities were multiplied by the appropriate
dilution factor. To obtain dynamic quenching constants for each ALAS2 variant,
emission intensities at 330 nm were graphed against the acrylamide
concentration in Stern-Volmer plots to linear Equation 3.1

in which Fo is the fluorescence intensity without quencher, F is the fluorescence
intensity with quencher, kq is the quencher rate coefficient, τ0 is the lifetime of the
emissive state of tryptophan without quencher present, Q is the concentration of
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the quencher acrylamide, and KSV is the dynamic quenching constant of
acrylamide for the tryptophans of hALAS2.

Circular dichroism (CD) spectroscopy—CD spectra were recorded using a
JASCO J-815 spectrometer. For far-ultraviolet (UV) CD, the proteins were at 0.1
mg/mL in 20 mM sodium phosphate, pH 8.0 in a cuvette with a 1.0 mm path
length. Spectra covered a 260-190 nm range and were collected at 25°C and a
scan speed of 20 nm/minute with a 0.1 nm step size and 1.0 nm bandwidth. Four
spectra were accumulated and averaged for each sample. For near UV and
visible CD, the proteins were prepared at 1.0 mg/mL in 20mM sodium phosphate,
pH 8.0, in a cuvette with a 1.0 cm path length. Spectra were recorded between
500-260 nm at 25°C at a scan speed of 20 nm/minute. Three spectra were
accumulated and averaged for each sample.

Results
Kinetic characterization of the XLEPP variants at 37°C—Steady-state
kinetic parameters were determined with respect to substrates glycine and
succinyl-CoA (Table 3.2) and compared to the published parameters, which were
acquired at 30°C for wild-type hALAS2 and the XLEPP variants (22). The
catalytic constant (kcat) value determined for the wild-type enzyme was 0.27 s-1,
and the Km values for glycine and succinyl-CoA were 12.6 mM and 6.1 µM,
respectively. DelAT, which exhibited a kcat value 3-fold higher than that of wild118

type hALAS2 at 30°C (22), had a 3-fold kcat value than the wild-type hALAS2 at
37°C, indicating that delAT has remarkably different thermodynamic properties
and may be less stable than wild-type hALAS2. The kcat values for delAGTG and
Q548X were increased in comparison to the wild-type enzyme by 1.7-fold and
1.4-fold, respectively. DelAGTG exhibited increased affinities for both glycine and
succinyl-CoA, while Q548X only had an increased affinity for succinyl-CoA. Of
the XLEPP variants tested alongside wild-type hALAS2, delAGTG, with its
extended C-terminus, generated the greatest effects on kcat values and substrate
affinities.

Table 3.2. Kinetic parameters for human wild-type ALAS2 and XLEPP
variant enzymes at 37°C.
Enzyme
Wild-type
DelAT
DelAGTG
Q548X

(sec-1)

(µM)

(sec-1µM-1)

(mM)

(sec-1mM-1)

0.27 ± 0.02
0.09 ± 0.01
0.45 ± 0.05
0.39 ± 0.04

6.1 ± 3.7
2.5 ± 1.3
3.6 ± 2.0
4.2 ± 2.2

0.05 ± 0.03
0.04 ± 0.02
0.13 ± 0.08
0.09 ± 0.05

12.6 ± 0.2
18.0 ± 7.6
4.2 ± 1.3
22.0 ± 3.8

0.021 ± 0.002
0.005 ± 0.003
0.108 ± 0.045
0.018 ± 0.005

HeLa and K562 cells expressing XLEPP variants accumulate more PPIX
than cells expressing wild-type hALAS2—The extent to which the XLEPP
variants might lead to PPIX accumulation was evaluated ex vivo in HeLa and
K562 cells. In HeLa cells, in comparison to expression of wild-type hALAS2,
delAT, delAGTG, and Q548X increased PPIX by 2.9-fold (p<0.05), 3.6-fold
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(p<0.01), and 3.7-fold (p<0.01), respectively (Figure 3.1). In K562 cells, delAT,
delAGTG, and Q548X increased PPIX by 1.6-fold (p<0.05), 1.6-fold (p<0.05),
and 2.1-fold (p<0.01), respectively. Expression of delAT, delAGTG, or Q548X
resulted in significantly increased PPIX accumulation in mammalian cells in
comparison to expression of wild-type hALAS2, indicating that the XLEPP
variants are stable in the cellular environment.

Glycine supplementation of the culture medium only increases PPIX
accumulation in HeLa cells expressing XLEPP variants with an increased affinity
for glycine—Since the XLEPP variants have variable affinities for glycine (Table
3.2), we set out to examine if glycine has a similar effect in mammalian cells
expressing

XLEPP

variants.

In

cells

expressing

wild-type

hALAS2,

supplementation of the media with 100 mM glycine increased the PPIX by 2-fold
(p<0.05) and in cells expressing delAGTG, PPIX increased by 1.5-fold (p<0.01)
(Figure 3.2). However, the effect of glycine supplementation on cells expressing
delAT and Q548X did not reach statistical significance (p>0.05). These data
corroborate the steady-state kinetic characterizations at 37°C that indicate that
delAGTG, in contrast to delAT and Q548X, has an increased affinity for the
glycine substrate.

The XLEPP variants are more thermostable than wild-type hALAS2—To
better understand the relationship between kinetics and temperature on the
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XLEPP variants, we placed the enzymes at a range of temperatures prior to
testing catalytic activity. Interestingly, the variants, especially delAT, were more

Figure 3.1. Expression of XLEPP variants in mammalian cells results in
accumulation of PPIX. HeLa cells are indicated by vertical-striped bars, while K562
cells are represented by checkered bars. The hALAS2 variants shown are wild-type
enzyme (blue), delAT (purple), delAGTG (pink), and Q548X (green). Mean PPIX
fluorescence values are representative of three separate experiments ± standard
deviation (*p<0.05 and **p<0.01, Student’s t-test) [a.u., arbitrary units].

sensitive to slight temperature increases up to 45°C (Figure 3.3). However, at
temperatures above 50°C, wild-type hALAS2 lost all measurable activity whereas
the delAT and delAGTG variants retained 7% and 11 % of their initial activity,
respectively, at 70°C. The K1/2 values, defined as the observed temperatures at
which the enzymes lost 50% of their initial activity, were 48.6°C, 52.5°C, 49.9°C,
and 51.4°C, for wild-type hALAS2, delAT, delAGTG, and Q548X, respectively.
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Figure 3.2. Glycine supplementation of the culture medium only increases PPIX
accumulation in cells expressing XLEPP variants with an increased affinity for
glycine. Plus (+) signs indicate samples in which the culture medium was supplemented
with 100 mM glycine, and minus (-) signs indicate samples in which no glycine was
added. The hALAS2 variants shown are wild-type hALAS2 (blue), delAT (purple),
delAGTG (pink), and Q548X (green). Mean PPIX fluorescence values are representative
of three separate experiments ± standard deviation (*p<0.05 and **p<0.01, Student’s ttest) [a.u., arbitrary units].

The XLEPP variants undergo significant changes in secondary structure
upon succinyl-CoA binding—Structural changes among wild-type hALAS2 and
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the XLEPP variants were evaluated using CD spectroscopy from 260 nm to 190
nm. ALAS undergoes a conformational change upon binding of its substrates
(28-31), and thus we examined the change in secondary structure of wild-type
hALAS2 and the XLEPP variants upon addition of succinyl-CoA. The CD spectra
for wild-type hALAS2 and the XLEPP variants indicated presence high degree of
α-helical content, consistent with the crystal structure of R. capsulatus ALAS
(32,33) (Figure 3.4). Binding of succinyl-CoA resulted in a very minor change in
secondary structure for wild-type hALAS2 (Figure 3.4A), but caused more
significant alterations in the secondary structure of the XLEPP variants, as noted
by the increases in mean residue molar ellipticity at 210 nm and 222 nm (Figure
3.4B-D).

Figure 3.3. Thermostability profiles vary for hALAS2 and XLEPP variants. Data are
averages of three independent experiments and are fit to the sigmoidal equation y=
a/(1+e(-(x-x0)/b)). The observed K1/2 values were 48.6°C, 52.5°C, 49.9°C, and 51.4°C, for
wild-type hALAS2 (blue), delAT (green), delAGTG (pink), and Q548X (purple),
respectively.
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Figure 3.4. Circular dichroism spectra of hALAS2 and the XLEPP variants in the
far-UV nm region. (A) Wild-type hALAS2, (B) delAT, (C) delAGTG, (D) Q548X. The
spectra for the holoenzymes are shown in each panel in solid lines, and the spectra for
the enzymes in the presence of 50 μM succinyl-CoA are in dotted lines. The
concentrations of enzyme were 0.1 mg/mL in 20 mM phosphate buffer, pH 8.0.

The tertiary structures and PLP-binding properties of the XLEPP variants
are distinct from those of wild-type hALAS2—Possible structural differences
between hALAS2 and the XLEPP variants were also analyzed by quantifying the
concentration of acrylamide required to quench the intrinsic fluorescence of
buried tryptophan residues in the enzymes (Figure 3.5). Dynamic quenching
constants were calculated using Stern-Volmer plots of the resultant data, as
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defined by Equation 1, for wild-type hALAS2, delAT, delAGTG, and Q548X of
1.42 M-1, 5.29 M-1, 1.92 M-1, and 2.54 M-1, respectively. The increased KSV values
observed with the XLEPP variants indicated that the tryptophans of the variants,
especially those of delAT, were more accessible to the aqueous solvent than
those of wild-type hALAS2.

Figure 3.5. Stern-Volmer plots displaying fluorescence quenching of buried
tryptophan residues in hALAS2 variants. Wild-type hALAS2, delAT, delAGTG, and
Q548X are shown in blue, green, pink, and purple, respectively. In each case the
enzyme concentration was 2 µM, and buffer was 20 mM phosphate, pH 8.0.

The differences in tryptophan fluorescence as observed by acrylamide
fluorescence quenching were further investigated by using near-UV CD and CD
in the visible light region, to analyze tertiary structure and the structural integrity
of the PLP binding site, respectively. Each of the XLEPP variants had a distinct
CD spectrum in the near UV region, indicating slight changes in the tertiary
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structure as visualized by changes in mean residue molar ellipticity bands at
wavelengths corresponding to aromatic residues (260-295 nm) (Figure 3.6A). In
the visible region, intense bands at 330 nm, indicative of PLP bound in the active
site of ALAS2 were observed with the delAGTG and Q548X XLEPP variants,
(Figure 3.6B). Wild-type hALAS2 and all three XLEPP variants displayed intense
molar ellipticity bands around 430 nm, which also signified PLP bound in the
active site.

Figure 3.6. Circular dichroism spectra in the near-UV and visible region. (A) Wildtype hALAS2, (B) delAT, (C) delAGTG, (D) Q548X are shown in blue, green, pink, and
purple, respectively. The concentrations of enzyme were 1.0 mg/mL in 20 mM
phosphate buffer, pH 8.0.
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Succinyl-CoA binding caused secondary structural changes in the XLEPP
variants to a greater extent than wild-type hALAS2 (Figure 3.4). CD was used to
further assess the effects of succinyl-CoA binding on both the tertiary structures
and integrity of the PLP-binding sites of the purified enzymes. While the tertiary
structures of wild-type hALAS2 and delAT were only slightly changed upon
binding of succinyl-CoA (Figure 3.7A-B), delAGTG and Q548X displayed rightshifted 330 nm bands and changes in positioning of the aromatic amino acids
(Figure 3.7C-D), suggesting these variants undergo significant changes in the
positioning of PLP in the active site.

Figure 3.7. Circular dichroism spectra in the near-UV and visible region in the
presence of 50 μM succinyl-CoA. (A) Wild-type hALAS2, (B) delAT, (C) delAGTG, (D)
Q548X are shown in blue, green, pink, and purple, respectively. The concentrations of
enzyme were 1.0 mg/mL in 20 mM phosphate buffer, pH 8.0.
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Discussion
Multiple molecular mechanisms, including changes in enzyme kinetics,
stability, rate of degradation, structure, and/or interaction with the regulatory βsubunit of the ATP-specific isoform of succinyl-CoA synthetase (SCS-βA) can
contribute to the decreases in ALAS2 activity observed in XLSA, (16,34), and
each of these mechanisms might also be operative in the gain-of-function
mutations resulting in XLEPP. Previously we (22) and others (21,23) have
demonstrated that purified recombinant XLEPP variants are more active than the
wild-type hALAS2, at least at 30°C. In this study, we report that the XLEPP
variants differ in their substrate affinities, thermostabilities, secondary structures
upon substrate binding, tertiary structures, and PLP-binding site integrity.
Deleting the C-terminal 33 amino acids of hALAS2, which are conserved
in higher eukaryotes but not present in prokaryotes, results in increased catalytic
activity (21). Furthermore, when this variant is expressed in HEK293 human
embryonic kidney cells, there is an increase in protein stability as shown by lack
of degradation in comparison to wild-type hALAS2 (21). In addition to the
truncated variant, two XLSA variants with point mutations near the C-terminus,
V562A and M567I, have been cloned and reported to have altered activities and
stabilities (21). Interestingly, the purified V562A enzyme exhibits higher catalytic
activity, but has a shorter half-life in transfected cells, while in contrast, the
purified M567I enzyme loses 75% of catalytic activity in comparison to wild-type
hALAS2, but has an extended half-life when expressed in human embryonic
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Figure 3.8. The citric acid cycle and heme synthesis. ALAS activity couples heme
production to aerobic respiration via common use of succinyl-CoA. The common usage
of succinyl-CoA as substrate implies close proximity of the 2 enzymes in vivo.

kidney (HEK293) cells. These results emphasize that the hALAS2 C-terminal
extension is clearly significant in determining the activity and stability of the
mammalian enzyme.
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The C-terminus is also important for protein-protein interaction of hALAS2
with SCS- A (16) (Figure 3.8). Wild-type hALAS2 and two XLSA variants, R411C
and M426V, associate with SCS- A, while another XLSA variant, D190V, loses
its ability to interact with SCS- A (34). Two XLSA variants with mutations near
the C-terminus, M567V and S568G, and a C-terminal truncated variant (F557X)
were reported to have normal or enhanced activity and stability, but none of them
bound to SCS- A, whereas wild-type hALAS2 bound strongly (16). Intriguingly,
delAT also leads to a mutation at the same methionine residue, M567E, which is
followed by a premature stop codon. Unlike the M567V variant, delAT still
strongly binds SCS- A (16). These data, along with studies on other variants with
mutations at the C-terminus (16), imply that the interaction of ALAS2 and SCSA is essential for full activity in vivo, and that one region vital for this interaction
lies between R559 and S568. In a cellular environment, the interaction of the
XLEPP variants and SCS- A is likely critical for their increased activity and
resulting PPIX accumulation (Figures 3.1 and 3.2).
The kcat values for the XLEPP variants measured using purified
recombinant enzyme, determined at 30 C, ranged from 3- to 3.4-fold greater than
that of wild-type hALAS2 and the specificity constants toward succinyl-CoA
(

) were increased up to fourteen-fold (22). The “gain-of-function

domain,” was previously concluded to extend over a minimum of 33 amino acids
of ALAS2 between residues G544 and G576 (22). Here we determined the kcat
values for the XLEPP variants at 37°C, as experiments with hyperactive mouse
ALAS2 variants have shown that activation energies among variants can vary
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widely, and elevated activity at lower temperatures does not always equate to
elevated activity at physiological temperature (35). The kcat value for wild-type
hALAS2 exhibited a 9-fold increase in activity when the temperature increased
from 30°C to 37°C, whereas the kcat value for delAT remained similar between
30°C (22) and 37°C (Table 3.2). The kcat value for delAGTG increased by 4-fold
and for Q548X increased by 4.3-fold. It is possible that the interaction of ALAS2
with the SCS-βA provides stabilization for ALAS2 in vivo, which could explain
why we found delAT to be less active in vitro at 37°C in the absence of SCS-βA,
but more active when HeLa cells and K562 cells were transfected with an
expression plasmid for delAT than wild-type hALAS2.
The purified XLEPP variants are more stable at temperatures above 55°C
(Figure 3.3), indicating that the increased thermostabilities of the variants is
independent of interaction with SCS and proteolytic susceptibility. These results
led us to examine the secondary and tertiary structures of wild-type hALAS2 in
relation to those of the XLEPP variants using CD and fluorescence
spectroscopies. The far-UV spectra for hALAS2 and the XLEPP variants are
indicative of a predominantly α-helical structure, and are similar among the
variant and wild-type proteins (Figure 3.4). However, upon addition of succinylCoA, the XLEPP variants undergo a much larger structural rearrangement than
the wild-type enzyme. These enhanced structural changes may explain the
increased affinities of the XLEPP variants for succinyl-CoA.
CD spectral signals in the near-UV region arise from the aromatic amino
acids, and the intensities of these signals are sensitive to the tertiary structure of
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the protein (32). Generally, tryptophan shows a spectral band close to 290 nm,
tyrosine a band between 275 and 282 nm, with a shoulder at longer wavelengths
often obscured by bands due to tryptophan, and phenylalanine shows weaker but
sharper bands between 255 and 270 nm (32). The actual shape and magnitude
of the near-UV CD spectrum of a protein will depend on the number of each type
of aromatic amino acid present, their mobility, the nature of their environment (Hbonding, polar groups and polarizability) and their spatial disposition in the
protein (32). Notably, wild-type hALAS2 and each XLEPP variant differ in the
number of specific aromatic amino acids. Wild-type hALAS2 has 5 tryptophans,
15 tyrosines, and 26 phenylalanines, whereas delAT is missing 1 tryptophan, 3
tyrosines, and 1 phenylalanine. DelAGTG lacks the same aromatic amino acids
as delAT, but has a tryptophan in its extended C-terminus, and Q548X lacks an
additional 2 phenylalanines in comparison to delAT (Table 3.1). Each variant has
a distinct near-UV spectrum that differs from that of the wild-type enzyme not
only in intensity, but also in shape (Figure 3.6). The divergent tertiary structures
of the variants (Figures 3.5 and 3.6) might help explain why the variants are more
active than wild-type hALAS2. For instance, if the kcat value for hALAS2 is
dependent on the conformation adopted by the protein, as has been shown to be
the case for mouse ALAS2 (2), a looser, more conformationally dynamic
structure in the XLEPP variants could result in higher activity. However, in the
absence of high-resolution 3-dimensional structures of wild-type hALAS2 and the
XLEPP variants, it is difficult to postulate exactly what these structural changes
are and precisely why they are associated with increased activity.
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Enzyme cofactors that absorb in the visible region of the electromagnetic
spectrum, such as PLP, show CD signals in the visible region only when bound
to their protein partner in sites which confer chirality. These CD signals are thus
excellent indicators of the integrity of the cofactor-binding site (32). PLPdependent absorption maxima at 330 and 420 nm are considered to be
characteristic of different ionization states of the internal aldimine bond between
the PLP and the ALAS, corresponding to the unprotonated and protonated forms,
respectively (36-39). The binding of delAGTG and Q548X to PLP results in
intense spectral bands around 330 nm that are not evident in the spectra of the
wild-type hALAS2 or delAT (Figure 3.7A-B). The spectra of delAGTG and Q548X
also display slightly higher intensity spectral bands between 420-430 nm (Figure
3.7C-D). PLP thus appears to bind these variants more tightly in both ionization
states, which is again consistent with the enhanced activity of these variants in
vivo. Upon addition of succinyl-CoA, the 330 nm-band observed in the spectra of
the delAGTG and Q548X variants is red-shifted to a broader band from 340-400
nm, indicating a substantial change in the chirality of PLP in the active site when
succinyl-CoA is bound.
In conclusion, these studies represent the first structural evaluations of the
XLEPP variants of hALAS2. We provide evidence that XLEPP can be modeled in
cell culture, and this model may aid in testing for direct action of potential
therapeutics on hALAS2. We also found that the XLEPP variants are more
thermostable, undergo more extensive conformational changes upon the addition
of succinyl-CoA, and differ in terms of tertiary structure and PLP binding. Future
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studies should aim to solve the crystal structure of hALAS2 and to discover
effective therapeutics for the treatment of XLEPP.
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CHAPTER 4: ISONIAZID INHIBITS HUMAN ERYTHROID
5-AMINOLEVULINATE SYNTHASE
Abstract
Mutations in the C-terminus of human erythroid 5-aminolevulinate
synthase (hALAS2) can result in two very different diseases, X-linked
sideroblastic anemia (XLSA) and X-linked erythropoietic protoporphyria (XLEPP).
XLSA patients have hALAS2 mutations that decrease activity, while mutations
associated with XLEPP result in a gain-of-function of hALAS2. XLEPP has only
recently been characterized, and thus there are no specific treatments. One
potential treatment involves the use of the antibiotic isonicotinic acid hydrazide
(isoniazid, INH), commonly used to treat tuberculosis, as INH can cause
sideroblastic anemia as a side-effect. INH has traditionally been thought to cause
anemia by limiting PLP availability to hALAS2 via direct inhibition of pyridoxal
kinase, and reacting with pyridoxal to form pyridoxal isonicotinoyl hydrazone. We
postulated that in addition to PLP-dependent inhibition of hALAS2, INH directly
acts on hALAS2. Using FACS and confocal microscopy, we show here that INH
reduces protoporphyrin IX accumulation in HeLa cells expressing either wild-type
human hALAS2 or XLEPP variants. In addition, PLP and PMP restored cellular
hALAS2 activity in the presence of INH. Kinetic analyses with purified hALAS2
demonstrated non-competitive or uncompetitive inhibition with an apparent Ki of
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1.5 µM. Circular dichroism studies revealed that INH triggers structural changes
in hALAS2 that interfere with the association of hALAS2 with its PLP cofactor.
These studies demonstrate that hALAS2 can be directly inhibited by INH,
provide insight into the mechanism of inhibition, and support the prospective use
of INH in treating patients with XLEPP and potentially other cutaneous
porphyrias.

Introduction
5-Aminolevulinate synthase (ALAS; EC 2.3.1.37) is a pyridoxal 5’phosphate (PLP)- dependent enzyme that catalyzes the first and rate-limiting
reaction in heme biosynthesis, the condensation of glycine and succinyl-CoA to
form 5-aminolevulinate (ALA), CoA, and CO2 (1-3). Two genes, ALAS1 and
ALAS2, encode the housekeeping and erythroid-specific ALAS isoforms,
respectively (4,5). ALAS2 is expressed specifically in developing erythrocytes,
where high levels of heme are required for hemoglobin production. Mutations in
human ALAS2 (hALAS2) are associated with two different diseases, X-linked
sideroblastic anemia (XLSA; MIM# 300751) (6,7) and X-linked erythropoietic
protoporphyria (XLEPP; MIM# 300751) (8,9). XLSA patients have mutations in
hALAS2 that result in decreased activity (7,10); approximately 50% of these
patients are pyridoxine-responsive (10-12). Mutations associated with XLEPP
have only been observed in exon 11, which encodes the C-terminus, and result
in a gain-of-function of hALAS2 (9). Accordingly, a “gain-of-function” domain has
been identified in the C-terminus of hALAS2 with a minimal length of 33 amino
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acids, ranging from G544 to G576 (13). XLEPP patients experience extreme,
painful photosensitivity due to porphyrin accumulation in the skin and, in some
cases, abnormal liver function that can lead to liver failure (9). XLEPP has only
recently been characterized, as patients had been misdiagnosed with
erythropoietic protoporphyria (EPP), which is most commonly caused by
mutations in ferrochelatase, the final enzyme of heme biosynthesis (9).
Interestingly, administration of the antibiotic isonicotinic acid hydrazide
(isoniazid, INH), which has been widely used for the treatment of tuberculosis,
induces sideroblastic anemia in some patients (6,14-16). INH has been proposed
to cause sideroblastic anemia through two mechanisms: inhibition of pyridoxal
kinase activity (17,18)

or INH reaction with pyridoxal to form an inactive

pyridoxal hydrazone (19,20). Both mechanisms result in reduced PLP levels, and
thereby lower hALAS2 activity. In 1979, Konopka and Hoffbrand tested the effect
of isoniazid on hALAS2 in erythrocyte homogenates from normal bone marrow
and found that INH inhibited the hALAS2 activity dose-dependently (21).
Additionally, they examined bone marrow from a patient with INH-induced
sideroblastic anemia and found that hALAS2 activity of bone marrow could be
restored to normal levels in vitro with supplementation of PLP (21). Based on
these findings the investigators concluded that INH functioned as a pyridoxine
antagonist, and thus indirectly inhibited hALAS2 (21).
INH is currently in a clinical trial enrolling EPP and XLEPP patients, (NCT
ID# NCT01550705), with the rationale that limiting vitamin B6 cofactor may
reduce hALAS2 activity, thereby dereasing the amount of PPIX accumulation, but
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the effect of INH on purified hALAS2 has not been reported. Since there are at
least 56 different human genes known to encode PLP-dependent enzymes (22),
and yet hALAS2 can apparently be selectively inhibited during INH treatment for
tuberculosis, we hypothesized that INH might directly bind to and inhibit hALAS2.
This hypothesis supports INH as a very logical treatment for cutaneous
porphyrias like EPP and XLEPP, caused by disruption of heme biosynthesis and
subsequent porphyrin accumulation.
Here we report that the results of cell culture studies support previous
conclusions on the effect of INH on hALAS2 activity and the ability of PLP to
reverse INH inhibition of hALAS2. Our studies using purified recombinant
hALAS2 showed that INH can alter the tertiary structure of hALAS2, decrease
the binding of PLP to hALAS2, and directly inhibit hALAS2 activity. We provide
insight into its direct mechanism of inhibition and offer further evidence for using
INH to treat patients with XLEPP and other cutaneous porphyrias.

Materials
Reagents—Aprotinin,

pepstatin,

leupeptin,

PMSF,

ampicillin,

β-

mercaptoethanol, pyridoxal 5’-phosphate, succinyl-CoA, thiamine pyrophosphate,
and NAD+ were obtained from Sigma-Aldrich Chemical Company. Glucose,
glycerol, acetic acid, methanol, glycine, disodium hydrogen orthophosphate,
sodium dihydrogen orthophosphate, DMSO, EDTA, MOPS, tryptone, yeast
extract, sodium chloride, tricine, ammonium sulfate, and potassium hydroxide
were purchased from Fisher Scientific. Centricon concentrators were from
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Millipore. Sodium dodecyl sulfate polyacrylamide gel electrophoresis reagents
and Phusion DNA Polymerase were acquired from Thermo Scientific. 5Aminolevulinic acid hydrochloride, isonicotinic acid hydrazide, and pyrazinamide
were purchased from Acros Organics. 1, 1-Dimethylhydrazine was purchased
from SPEX Certiprep group. BmtI, SalI, BlpI, and BamHI restriction enzymes
were obtained from New England BioLabs, Inc. Gentamicin sulfate and RPMI1640 culture medium were procured from Mediatech, Inc. Oligonucleotides were
synthesized by Integrated DNA Technologies. T4 DNA ligase and ligase buffer
were obtained from Thermo Scientific Fermentas and a bicinchoninic acid protein
determination kit was purchased from Thermo Scientific Pierce.

Methods
Plasmids for mammalian expression and protein purification—For
expression plasmids used in the transfection of mammalian cells, the wild-type
precursor ALAS2 cDNA (GenBank: X56352.1) was subcloned into the multiple
cloning site of the pIRES2-ZsGreen1 vector (purchased from Clontech
Laboratories, Inc. Mountain View, CA) using the BmtI and BamHI restriction sites
as described previously (Chapter 3, pages 109-112). The resulting plasmid was
named pEF27. For the mammalian expression plasmids encoding the precursor
XLEPP variants, the cDNAs encoding the mutated hALAS2 C-termini were
subcloned into pEF27 and the resulting plasmids were named pEF28 and
pEF29, encoding delAT and delAGTG, respectively, as described previously
(Chapter 3, pages 110-112). To purify hALAS2 and the XLEPP variant proteins
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using nickel affinity chromatography, we added six histidine codons to the cDNA
sequence encoding the mature N-terminus of hALAS2, and subcloned the
digested PCR products into plasmids expressing wild-type hALAS2 and
delAGTG, as described previously (Chapter 3, pages 111-112). The resulting
plasmids, pEF40 and pEF42, were used for the expression of histidine-tagged
wild-type hALAS2 and delAGTG, respectively.
Cell culture—Human cervical carcinoma (HeLa) cells were maintained in
DMEM with 4.5 g/L glucose, L-glutamine, and sodium pyruvate (Mediatech, Inc.),
with 10% fetal bovine serum (FBS) (Thermo Scientific™ HyClone™), gentamicin
(Mediatech, Inc.; 50 μg/mL), penicillin (Mediatech, Inc.; 60 μg/mL) and
streptomycin (Mediatech, Inc.; 100 g/mL) at 37°C under 5% CO2 in a humidified
incubator.
Transient transfection of HeLa cells—HeLa cells were transfected using
DNA-Lipofectamine™ LTX transfection reagent as previously described (Chapter
3, page 112). For cells treated with INH, INH dissolved in DMSO (10 mg/mL) was
added to the culture medium 24 hours post-transfection to allow for
protoporphyrin IX (PPIX) accumulation caused by hALAS2 expression, as
described with murine ALAS2 (E. J. Fratz, G. A. Hunter, and G. C. Ferreira,
unpublished observations). As a control, DMSO (10 mg/mL) was added to nontransfected and transfected cells in culture medium at the same time point (i.e.,
24 h). Pyridoxine-HCl, PLP, and pyridoxamine-5’-phosphate (PMP) were
dissolved in DMEM (10 mg/mL) and added to the culture medium 24 hours post146

transfection. The final pyridoxine, PLP and PMP concentrations were each 100
μg/mL in all experiments.

Preparation of cells for FACS and quantitation of PPIX—HeLa cells were
prepared for FACS and PPIX was quantitated as previously described (Chapter
3, pages 114-115).

Confocal

fluorescence

microscopy—HeLa

cells

were

grown

in

Thermoscientific™ Nunc™ Labtek™ sterile 4-well chambered coverglass until
50% confluent, and then transfected as described above. Twenty-four hours
later, the culture medium was supplemented with INH to yield final
concentrations of 100 μg/mL or 500 μg/mL. After an additional twenty-four hours,
and immediately before obtaining confocal fluorescence microscopy images of
the cells, the medium was removed from the wells and the cells were washed
with PBS three times. Live cell imaging was performed using a 3i-Olympus
spinning disk confocal microscope operated by Slidebook 5 software and
equipped with a Photometrics Evolve EMCCD camera. The filter block used
consisted of a 350/50 nm excitation filter, a BS400 beamsplitter, and a 630/75
nm emission filter.

Protein purification—Recombinant human ALAS2 and the XLEPP variants
were purified from BL21(DE3) E. coli cells containing the overexpressed protein
as described previously (Chapter 3, pages 115-117). Purity of the protein was
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assessed by SDS-PAGE and protein concentration was determined by the
bicinchoninic acid (BCA) assay and bovine serum albumin as the standard as
described previously (Chapter 3, page 117).

ALAS

colorimetric

activity

assay—ALAS

activity

was

determined

according to the method of Lien and Beattie (23) with minor modifications. Prior
to the activity assay, purified recombinant wild-type hALAS2 in 25 mM HEPES,
pH 7.2, containing 10% glycerol, was incubated with INH (0-1 mM), for 15
minutes at 37°C. After the addition of the succinyl-CoA and glycine substrates,
the reactions proceeded, for 10 minutes at 37°C. The final concentrations of
ALAS, succinyl-CoA and glycine were 1.5 µM, 100 μM and 100 mM for each
assay. For the PLP-dependence assays, INH was first incubated with PLP for 15
minutes at 37°C and then the purified recombinant wild-type hALAS2, which is
PLP-bound, was added for a 15 minute incubation at 37°C before beginning the
ALAS activity assay as described above. The concentrations of added PLP
ranged from 0 μM to 40 μM. For the glycine competition assays, ALAS2 activity
was determined using glycine concentrations ranging from 10 mM to 150 mM,
and INH concentrations from 0 μM to 100 μM. Succinyl-CoA and hALAS2
concentration were held constant at 100 μM and 1.5 μM, respectively. To
determine the apparent Vmax and Km values for glycine, and the apparent Ki for
INH, the data were first fit using Sigmaplot graphing software to Equation 4.1
(24),
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(4.1)

where y is the activity as measured by rate of ALA formation, x is either the
concentration of glycine or INH, and Kx is either the apparent Ki for INH or Km for
glycine. From these primary plots, the apparent maximal velocities were in turn
used to construct secondary plots defining Vmax and Ki values. In addition, the
glycine competition data were independently analyzed using Dynafit model
discrimination software (25,26) to compare competitive, mixed, and partial
inhibitory mechanisms. For illustration purposes, glycine competition data were
evaluated using a Lineweaver-Burke plot to display the nature of the inhibition.
Also for illustration purposes, the raw data were fit using Sigmaplot graphing
software to a sigmoidal Equation 4.2

(4.2)

where y is the percentage of ALAS activity loss and x is log of the INH
concentration.

Circular dichroism (CD) spectroscopy—CD spectra were recorded using a
JASCO J-815 spectrometer as described previously (Chapter 3, page 119).

Results
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INH reduces PPIX accumulation in HeLa cells expressing wild-type
hALAS2 and XLEPP variants—To test the ability of INH to reduce ALAS2 activity
and PPIX production in cell culture, we transfected HeLa cells with expression
plasmids encoding wild-type hALAS2 (WT) and two XLEPP variants, delAT and
delAGTG, which have increased ALAS activity. At a concentration of 5 g/mL,
INH did not cause a significant decrease in PPIX fluorescence, and thus PPIX
accumulation, in cells expressing WT, delAT, or delAGTG (Figure 4.1). An INH
concentration of 50 g/mL was sufficient to decrease PPIX levels in delAGTGexpressing cells (p<0.05), and INH concentrations of 100 g/mL and 200 g/mL

Figure 4.1. INH reduces PPIX accumulation in HeLa cells expressing wild-type
hALAS2 and XLEPP variants. Wild-type hALAS2 (WT)-, delAT-, and delAGTGexpressing HeLa cells were treated with 0, 5, 50, 100, or 200 µg/mL INH. Mean PPIX
fluorescence values are representative of three separate experiments ± standard
deviation (*p<0.05 and **p<0.01, Student’s t-test). [a.u., arbitrary units].
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further decreased the amount of PPIX accumulated by 36% and 53%,
respectively

(p<0.01). For WT-expressing cells, INH concentrations of 100

g/mL and 200

g/mL resulted in decreased PPIX accumulation (p<0.01), and

delAT-expressing cells required an INH concentration of 200

g/mL to reduce

PPIX production and accumulation (p<0.05).

INH reduces PPIX accumulation in both HeLa cells expressing delAGTG
and those adjacent to delAGTG-expressing HeLa cells—To examine the PPIX
accumulation and the effect of the INH treatment in individual cells, we used
confocal fluorescence microscopy to analyze ZsGreen1 fluorescence and PPIX
fluorescence. We chose to monitor delAGTG expression because it resulted in
the highest PPIX accumulation and largest percent decrease in PPIX when
treated with INH (Figure 4.1). HeLa cells that were not transfected (Figure 4.2A)
and HeLa cells that were transfected with the pIRES2-ZsGreen1 vector plasmids
(Figure 4.2B) were used as controls for no PPIX fluorescence and ZsGreen1
fluorescence, respectively. In delAGTG-expressing cells, PPIX fluorescence was
evident in nearly all cells, even though only approximately 25% of cells
expressed ZsGreen1 and delAGTG (Figure 4.2C). When delAGTG-expressing
cells were treated with either 100 or 500 g/mL INH, PPIX was visibly decreased
in all cells (Figure 4.2D and 4.2E).
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INH inhibition of ALAS2 activity is not affected by pyridoxine—Since the
two described mechanisms of INH inhibition of ALAS2 are PLP-dependent, and
oral pyridoxine can be effective in treating sideroblastic anemia acquired from

Figure 4.2. INH reduces PPIX accumulation in both HeLa cells expressing
delAGTG and those adjacent to delAGTG-expressing HeLa cells. Rows 1-4 of each
panel correspond to the images of 1. superimposed bright-field and fluorescence, 2.
green fluorescence 3. red fluorescence, and 4. overlaid red and green fluorescence,
respectively. (A) Non-transfected HeLa cells. (B) HeLa cells transfected with pIRES2ZsGreen1. (C) HeLa cells transfected with pEF29, which encodes both ZsGreen1 and
delAGTG. (D) HeLa cells transfected with pEF29, which encodes both ZsGreen1 and
delAGTG, treated with INH (100 μg/mL) for 24-hours. (E) HeLa cells transfected with
pEF29, which encodes both ZsGreen1 and delAGTG, treated with INH (500 μg/mL) for
24-hours. “Control” refers to non-transfected HeLa cells.
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prolonged INH treatment, we postulated that pyridoxine supplementation of the
cell culture medium could reverse the INH inhibition of ALAS2. Pyridoxine (100
g/mL) did not affect the PPIX levels in WT-, delAT-, or delAGTG-expressing
cells (p>0.1) (Figure 4.3). In cells treated with INH (100 g/mL), pyridoxine also
did not exhibit any effects on PPIX fluorescence (p>0.1), indicating that the
addition of pyridoxine is not sufficient to overcome the INH effect on ALAS2
activity.

FIGURE 4.3. INH inhibition of PPIX accumulation in HeLa cells expressing either
wild-type hALAS2 or XLEPP variants is not affected by pyridoxine. Mean PPIX
fluorescence values are representative of three separate experiments ± standard
deviation [a.u., arbitrary units].
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PLP and PMP reduce the effect of INH on ALAS2 inhibition—We next
examined whether supplementation of the cell culture medium with PLP or PMP
could reverse the INH inhibition of ALAS2 activity. In contrast to pyridoxine, both
PLP and PMP (100 g/mL) restored ALAS2 activity of INH-inhibited delAT and
delAGTG-expressing HeLa cells (p<0.05) (Figure 4.4). A similar trend was seen
in WT-expressing cells, but the changes did not reach statistical significance
(p>0.05).

FIGURE 4.4. Either PLP or PMP supplementation of the culture medium of HeLa
cells expressing wild-type hALAS2 or XLEPP variants reduces the inhibitory effect
of INH on PPIX accumulation. Mean PPIX fluorescence values are representative of
three separate experiments ± standard deviation (*p<0.05, Student’s t-test) [a.u.,
arbitrary units].
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INH inhibits purified hALAS2—Since our findings with hALAS2- and
XLEPP-expressing mammalian cells supported the proposition that inhibition of
hALAS2 activity by INH involves PLP depletion, we set out to determine if INH
could directly inhibit purified hALAS2, affect the availability of PLP, or if INH
worked through a combination of both mechanisms. In the presence of excess of
glycine (100 mM) and succinyl-CoA (100 µM) concentrations (i.e., over 10-fold
the Km values of the two substrates (13,27)), INH inhibited hALAS2 activity
(Figure 4.5A), and similarly, INH inhibited the ALAS activity of delAGTG (data not
shown). To determine if the depletion of PLP and consequent inhibition of the
purified hALAS2 resulted from the reaction between INH and the PLP cofactor or
a decrease in available PLP for binding to hALAS2 and formation of the active
holoenzyme, we included an additional step involving the incubation of INH with
PLP prior to the assay reaction. The greater Kiapp values for INH (from 2.7 to 10.6
µM) with increased PLP concentrations (Figure 4.5B) indicated that a portion of
the INH reacts with PLP in such a way that INH can no longer inhibit hALAS2. At
concentrations of INH of 10

M and below, preincubation of INH with PLP

reduced hALAS2 inhibition; however, 100

M INH caused nearly 100% activity

loss regardless of the concentration of PLP. In addition to these experiments in
which INH was incubated with PLP prior to mixing with hALAS2, similar
experiments were run in which hALAS2 (1.5 µM) was incubated with INH (0-100
µM) prior to mixing with PLP (0-40 µM) (data not shown). Regardless of the
concentration of PLP added to the hALAS2-INH, the apparent Vmax was
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unchanged, indicating that once INH is bound to hALAS2, PLP cannot reverse
inhibition.

INH is not a competitive inhibitor for glycine—We next investigated
whether INH competed with the glycine substrate for binding to the active site of
hALAS2 (Figure 4.6A-B). INH decreased the Vmax for glycine and increased the

FIGURE 4.5. INH inhibits the activity of purified hALAS2. A. Percent activity loss
values are representative of three separate experiments ± standard deviation. Data were
fit to Equation 2. B. INH inhibition of hALAS2 occurs in part independently of PLP
availability. Enzymatic activity was determined over a range of INH concentrations (1 –
100 µM), at constant hALAS2 concentration (1.5 μM), and at constant PLP
concentrations. Each data point represents the percentage activity loss either in the
absence (blue) or in the presence of different added concentrations of PLP: 5 μM
(green), 10μM (pink), 20 μM (cyan) and 40 μM (black). The corresponding colored
curves are the best fits of the data to Equation 1, and the the respective estimated Ki
values for INH are 2.7 μM, 5.1 μM, 7.5 μM, 9.7 μM and 10.6 μM. Activity loss values are
averages of three separate experiments.

Km for glycine (Figure 4.6A). The decrease in the Vmax for glycine with increased
INH concentration indicates that INH does not compete with glycine to bind to
hALAS2. From the secondary plot of these data fit to Equation 1, we determined
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the apparent inhibitory constant (Kiapp) to be 1.5

M. Dynafit analysis of the

kinetic data for INH inhibition excluded competitive and mixed inhibition, and
supported partial inhibition of the type in Scheme 1,

(1)

where E represents ALAS, S is the substrate glycine, P is the product, and I is
INH. The fitted parameters were 4.5 mM for the dissociation constant of glycine,
2.0 s-1 for kcat, 0.4 s-1 for k’cat, and 1.2 µM for the Kiapp of INH.
We also performed similar experiments to assess competition for succinylCoA binding, but the enzyme concentration was close to that of the Km for
succinyl-CoA (4.3 µM) (13), and the colorimetric assay was not sensitive enough
to attain reliable signal to noise ratio at succinyl-CoA concentrations below 10
µM. Thus, there was a high error associated with the Kiapp calculated from the
secondary plot of these data. While the apparent Km for each concentration of
INH could not be determined from the primary plot due to high error at succinylCoA concentrations less than 10 µM, a trend of decrease in the Vmax for succinylCoA as a result of increased INH concentrations was apparent (data not shown).
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Figure 4.6. INH does not compete with glycine to bind hALAS2. A. INH
concentrations are as follows: 0 µM (black), 2 µM (yellow), 5 µM (green), 10 µM (pink),
and 50 µM (blue). Data were fit to Equation 4.1. B. Lineweaver-Burke reciprocal plot
constructed using the data from primary plots. Activity values are averages of three
separate experiments.

Taken together, these findings indicate that INH inhibits hALAS2 in a dosedependent manner and does not directly compete for binding with either the
glycine or succinyl-CoA substrates.

The hydrazine moiety of INH is necessary, but not sufficient for complete
ALAS2 inhibition—Previously, using UV-visible absorption spectroscopy, we
determined that the addition of INH (100 µM) to the PLP-glycine aldimine (100
µM PLP and 10 mM glycine) disrupted the Schiff base linkage as monitored by a
decrease in absorbance at 420 nm (data not shown). Thus, we posited whether
the reactive hydrazine moiety of INH would be sufficient to inhibit hALAS2.
Pyrazinamide, an antibiotic also used to treat tuberculosis, has a similar size and
structure to INH, but has an amide group on a pyrazine ring instead of a
hydrazine group on a pyridine ring (Figure 4.7A, inset). To determine whether the
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hydrazine moiety of INH was the major contributor to the inhibition of hALAS2 by
INH, we compared the hALAS2 activity in the presence of INH, pyrazinamide, or
1,1-dimethylhydrazine (Figure 4.7B, inset). Of significance, patients treated with
pyrazinamide can also present anemia, which led us to hypothesize that hALAS2
might also be inhibited by this antibiotic (13,28). We found that while both
pyrazinamide (Figure 4.7A) and 1,1-dimethylhydrazine (Figure 4.7B) could
reduce hALAS2 activity, neither could inhibit hALAS2 to the same level as INH
(Figure 4.7A-B) suggesting that both the hydrazine moiety and structure of INH
are important for complete inhibition of hALAS2.

INH induces changes in the tertiary structure and PLP-binding to ALAS2—
Our activity assay data supported the hypothesis that INH can directly inhibit
hALAS2, but it was still unclear where and how INH binds to hALAS2. Since INH
was not a competitive inhibitor for glycine or succinyl-CoA, we hypothesized that
INH binds at an alternate site which results in a structural rearrangement that
lead to a diminishment in hALAS2 activity. Thus, we next examined the
secondary and tertiary structural changes induced in hALAS2 upon binding of
INH. CD spectroscopy revealed that while INH did not induce any major changes
in secondary structure (data not shown). INH altered the tertiary structure of
hALAS2 in a concentration-dependent manner, as visualized by changes in
mean residue molar ellipticity bands at wavelengths corresponding to aromatic
residues (260-295 nm) (Figure 4.8A). Specifically, INH decreases the tyrosine
and tryptophan signals, which show bands between 275 and 282 nm and at 290
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nm, respectively (29). INH also affected the visible region of the CD spectra; INH
decreased the mean residue molar ellipticity band between 420-440 nm, which
indicated that the orientation and positioning of PLP in the active site of hALAS2
was disrupted by INH (13,30) (Figure 4.9B). The decrease in mean residue molar
ellipticity exhibited an INH concentration dependence described by a hyperbolic
curve and a value of 53 M for the INH concentration at which the mean residue
molar ellipticity was one half of its maximal value. Similar to the activity of
hALAS2, the structural changes induced by INH were time-dependent. Because
we accumulated and averaged either 3 or 4 CD scans per variant, the structural
changes within the first 30 minutes could not be distinguished. There were,
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Figure 4.7. Pyrazinamide and 1,1-dimethylyhydrazine do not inhibit hALAS2. Wildtype hALAS2 was incubated with INH (black), (A) pyrazinamide (pink), or (B) 1,1,dimethylhydrazine (blue) ranging from 0 to 100 µM before measuring ALAS activity. The
structures for INH, pyrazinamide, and 1,1-dimethylhydrazine are provided as insets in
each graph. Percent activity loss values are representative of three separate
experiments ± standard deviation.

however, slight differences between the spectra of hALAS2 obtained immediately
after INH addition and spectra of hALAS2 incubated with INH for 24 hours (data
not shown), that indicated a time-dependence in the structural changes.
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The CD spectra for the delAGTG variant (Figure 4.9) differed from those
for wild-type hALAS2 (Figure 4.8A) in both the near UV and visible regions, with
the most obvious difference being the presence of a mean residue molar
ellipticity band at 330 nm for delAGTG (not present in the wild-type spectrum),
often associated with PLP bound to its protein partner in a site which confers
chirality (13,29). Similarly to wild-type hALAS2, INH altered the tertiary structure
of the delAGTG variant in a concentration-dependent manner (Figure 4.9A). INH
also affected the visible region of the CD spectra dose-dependently, as noted by
decreased mean residue molar ellipticity at the wavelengths associated with PLP
bound in the active site of hALAS2 (330nm and 420nm) (Figure 4.9B).

Figure 4.8. INH induces changes in the tertiary structure of ALAS2 and binding of
the PLP cofactor. (A) CD spectra in the near UV and visible region for wild-type
hALAS2 prior to reaction with INH (cyan) and after incubation with increasing
concentrations of INH up to 100 M (green). (B) The decrease in mean residue molar
ellipticity at 420 nm plotted against the concentration of INH. Data were fit to Equation
4.1.
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FIGURE 4.9. INH induces changes in the tertiary structure of delAGTG and binding
of the PLP cofactor. CD spectra in the near UV and visible region for delAGTG prior to
INH addition (―), and upon the addition of 60 M INH (- - -) and 100 M INH (·····).

Discussion
Isoniazid has a long history of being used to treat tuberculosis infections,
dating back to at least 1952 (31). Case studies reporting anemia as a common
side effect were reported as early as 1962, and continued as doctors began
expanding the use of isoniazid to treat tuberculosis patients (16,32-34). In some
cases, patients recover from the acquired anemia when taken off of isoniazid,
while others also require dietary pyridoxine supplementation to fully recover
(16,21,34-36). In general, pyridoxine supplements are given to patients taking
isoniazid in order to prevent onset of anemia (37). In addition to case studies in
tuberculosis patients, the effects of INH on erythropoiesis have been
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characterized in mice; when INH was administered during induced erythropoiesis
in mice, heme synthesis and erythroid maturation were inhibited (38).
INH is well-studied in patients treated for tuberculosis (14,39,40), and, in
Mycobacterium tuberculosis, INH is known to be activated by the katG enzyme
and subsequently to target enzymes required for mycolic acid synthesis (41-47),
However, the mechanism by which INH causes cell death remains elusive in
Mycobacterium tuberculosis (42), and metabolism of INH in human cells is not
well-investigated. Thus, in our studies, we explored the effects of INH in human
cell lines, focusing on elucidating the mechanisms of INH-induced anemia. Our
studies using mammalian cell cultures indicate that INH decreases PPIX
accumulation in HeLa cells overexpressing hALAS2 (Figure 4.1), thus decreasing
PPIX transported into surrounding cells (Figure 4.2), and demonstrate that INH is
effective in reducing hALAS2 activity ex vivo. While pyridoxine did not lessen the
effect of INH on PPIX levels (Figure 4.3), addition of either PLP or PMP
completely reversed the effects of INH (Figure 4.4).
The results of these initial experiments might be interpreted by using the
known PLP-dependent mechanisms of hALAS2 inhibition by INH, in which INH
inhibits pyridoxal kinase (17,18), the enzyme that produces PLP, and also reacts
with PLP to form pyridoxal isonicotinoyl hydrazones (19,20). However, it was still
unclear if INH had a more direct effect on hALAS2 activity that would better
explain the specific side effect of sideroblastic anemia. In order to reduce the
number of variables, we began in vitro experiments in which we could more
stringently control the experimental conditions. In doing so, we found that INH
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inhibits purified hALAS2 regardless of the presence of excess PLP (Figure 4.5B).
Excess PLP in the reaction buffer did affect the apparent Ki values for INH,
indicating that a small percentage of the INH might have reacted with PLP to
form pyridoxal-hydrazones (20), thus reducing the amount of INH available to
inhibit hALAS2. However, 100

M INH caused nearly 100% activity loss

regardless of the concentration of PLP (Figure 4.5B), suggesting a PLPindependent mechanism of hALAS2 inhibition by INH. We subsequently found
that INH is not a competitive inhibitor for either the glycine or succinyl-CoA
substrates, as it decreases the Vmax and increases the Km values for glycine, and
decreases the Vmax for succinyl-CoA. These data suggest that INH binds to an
alternate site distinct from the glycine-binding site and decreases the affinity of
hALAS2 for glycine.
Other antibiotic drugs commonly prescribed to treat tuberculosis, such as
pyrazinamide, chloramphenicol, and cycloserine, have also been associated with
drug-induced sideroblastic anemia (6,48). However, it has been noted that some
patients treated with a cocktail of antibiotics for tuberculosis can recover from
sideroblastic anemia by withdrawal of only INH from the cocktail (14). Since the
ability of pyrazinamide to induce sideroblastic anemia in patients is unresolved
(14,28,48), we examined whether pyrazinamide similarly affected hALAS2
activity. Pyrazinamide did not inhibit hALAS2 activity at concentrations below 30
µM, whereas 30 µM INH resulted in greater than 80% inhibition of hALAS2
activity (Figure 4.7). Structural comparison of INH and pyrazinamide suggested
that the hydrazine moiety of INH might be important for the inhibition of hALAS2.
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In order to ascertain if hydrazine was sufficient to react with and inhibit hALAS2,
we used 1, 1-dimethylhydrazine in our activity assay. At concentrations below 10
µM, 1,1-dimethylhydrazine resulted in modest activity loss, but even at
concentrations up to 500 µM, activity loss never reached 50%. Thus, both the
hydrazine moiety and the linkage of the hydrazine moiety on the pyridine ring of
INH appear crucial for complete inhibition of hALAS2.
The chemical mechanism of ALAS2 begins, in the absence of substrates,
with active site lysine 313 of ALAS2 bound to PLP forming an internal aldimine
(Figure 4.10). In the presence of substrates, the glycine binds first, followed by
transaldimination with the active site lysine to yield an external aldimine (49).
Next, the pro-R proton of glycine is abstracted by the active site lysine, followed
by condensation with succinyl-CoA and CoA release to generate an α-amino-βketoadipate intermediate. This step is followed by decarboxylation resulting in an
enol-quinonoid rapid equilibrium, then protonation of the enol to give an aldiminebound molecule of ALA, and ultimately release of the product (ALA) (49). Despite
the complexity of the proposed chemical mechanism, transient kinetic studies
have led investigators to propose that the rate-determining step of the ALAScatalyzed reaction is product release or a conformational change leading to
product release (49,50). It is the movement of the active site loop (51) towards
the open conformation that controls the rate at which ALA dissociates, and
therefore the overall catalytic rate (30,49,50,52,53). Since INH does not compete
with the substrates, one possibility is that binding of INH stabilizes the closed
conformation of hALAS2. INH could bind both the hALAS2 holoenzyme and
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FIGURE 4.10. Chemical mechanism of the ALAS2-catalyzed reaction. (I) ALAS2
internal aldimine, (II) glycine-ALAS2 external aldimine, (III) quinonoid intermediate I, (IV)
glycine-succinyl-CoA
condensation
intermediate,
(V)
α-amino-β-ketoadipate
intermediate, (VI) enol intermediate, (VII) quinonoid intermediate II, (VIII) ALA-ALAS2
external aldimine.

glycine-bound hALAS2, which is consistent with the Dynafit prediction of partial
inhibition (Scheme 1).
To better resolve the mechanism of inhibition, we examined the possibility
of secondary and tertiary structural changes associated with binding of INH to
hALAS2. We could not delineate significant secondary structural changes, but
the tertiary structure exhibited a distinct, concentration-dependent change upon
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incubation with INH. The changes in fluorescence of the aromatic residues of
hALAS2 as seen in these CD spectra (Figure 4.8A) indicate that INH elicits a
protein conformational change that renders the enzyme either less active or
inactive. CD spectroscopy also revealed a concentration-dependent decrease in
the mean residue molar ellipticity band between 420-440 nm, indicating that INH
disrupts the hALAS2-PLP bond, apparently yielding an enzyme devoid of the
Schiff base linkage (Figure 4.8A-B). Decreased PLP-binding of ALAS2 has been
noted previously with mouse ALAS2 when serine 254 was mutated to an alanine
residue (30). This active site mutation causes a change in the microenvironment
of the PLP cofactor and disrupts the binding of succinyl-CoA (30). We also
observed changes in tertiary structure and PLP-binding with the XLEPP variant
delAGTG (Figure 4.9). One possibility is that INH causes a structural change that
inhibits PLP binding, following either direct displacement or remote binding. This
could explain why excess PLP cannot completely reverse activity loss caused by
INH in vitro. In the cellular environment, ALAS2 is peripherally associated with
the mitochondrial membrane and is known to bind at least one other enzyme
partner, succinyl-CoA synthetase (12,54). INH might not bind as tightly or
displace PLP as effectively when ALAS2 is membrane- and/or protein-bound,
which might explain why PLP can reverse the INH inhibition ex vivo (21).
Here we provide evidence that INH directly inhibits purified hALAS2. Our
data suggest that INH is an inhibitor that affects the functionality of the PLP
cofactor. We propose a mechanism by which addition of INH to hALAS2 results
in structural rearrangement of the protein and disruption in the hALAS2-PLP
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linkage, thus inhibiting hALAS2 activity. To determine the position and location at
which INH binds to hALAS2, further studies including x-ray crystallization of
hALAS2 with INH are warranted. These data provide support for using INH to
treat cutaneous porphyrias, especially for XLEPP, where hALAS2 is overly
active. The direct effect of INH on hALAS2 activity should also be considered
when treating tuberculosis patients who have developed sideroblastic anemia.
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CHAPTER 5: SUMMARY AND CONCLUSION

This dissertation focuses on mutations in ALAS2 that lead to an increased
activity of the enzyme. ALAS2 can be used to produce the heme precursor PPIX,
which is used as a photosensitizer for PDT. Thus mutations in ALAS2 that
increase its activity offer a means to increase PPIX photosensitization. We
explored mutations located in the presequence known to alleviate the heme
feedback inhibition of ALAS2 translocation into the mitochondrion (1) and
mutations in the active site loop region known to increase ALAS2 activity (2,3),
and assessed the ability of the ALAS2 variants to accumulate PPIX in
mammalian cells and cause light-induced cell death. In humans, hALAS2
mutations in the C-terminus can result in increased activity and are associated
with XLEPP. We characterized mutations in the hALAS2 C-terminus associated
with XLEPP using purified recombinant hALAS2 and ex vivo in mammalian cells
in terms of their catalytic activity, substrate affinities, thermostability, cellular
activity, and structure. Since there are no specific treatments for XLEPP as of
yet, we evaluated the use of a potential drug, INH, to treat XLEPP by inhibiting
hALAS2. The conclusions presented add to the general knowledge of the
ALAS2-catalyzed reaction, further elucidate the mechanism of XLEPP, and
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provide evidence for isoniazid as an inhibitor of hALAS2, which has potential for
treating porphyria patients.
To restrict photosensitivity by biological, rather than just chemical or
physical means, we emulated an idea set forth by Gagnebin et al. (4) to deliver
ALAS to tumors for PDT not only for better targeting, but also for greater
photosensitivity (4). We used more highly active variants of mALAS2 (2,3) and
postulated that these variants would increase PPIX accumulation, phototoxicity,
and targeted cell death sufficiently to make the approach more clinically
attractive. The HeLa cells that accumulated the highest amount of PPIX were
those expressing R433K, an mALAS2 variant with mutated HRMs and the
arginine residue at position 433 in the active site loop mutated to a lysine.
Expression of R433K in HeLa cells produced a 2- to 3-fold increase in PPIX in
comparison to WT, and a 4- to 6-fold increase in PPIX fluorescence in
comparison to cells transfected with the pIRES2-ZsGreen1 vector control or
HeLa cells alone. When the culture medium was supplemented with glycine,
PPIX accumulation increased by 13- to 15-fold in comparison to cells transfected
with the pIRES2-ZsGreen1 vector control or HeLa cells alone, and represented
the conditions for the highest cellular PPIX accumulation. To study the
photosensitivity of cells that accumulated PPIX, we performed light treatments
using an incandescent lamp, which emits light in the visible and infrared spectral
regions (400-1000 nm). The highest cell death of up to 90% was seen in lighttreated HeLa cells expressing ZsGreen1 and R433K, in culture medium
supplemented with 100 mM glycine. This represents a substantial improvement
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over the 26% cell death reported previously (4), and indicates that this approach,
if carefully developed, may eventually find some clinical utility.
Next we studied mutations in the C-terminus of hALAS2 associated with
XLEPP that cause an increase in activity. Much like in XLSA, whereby multiple
molecular mechanisms can contribute to a decrease in hALAS2 activity, we show
that the XLEPP variants differ from wild-type and each other in their substrate
affinities, thermostability, secondary structure upon substrate binding, tertiary
structure, and integrity of the PLP-binding site. Kinetic analyses performed with
purified recombinant hALAS2 variants at 37°C revealed that delAT, in
comparison to wild-type hALAS2, exhibited a reduced catalytic efficiency for
glycine, but the efficiency for succinyl-CoA was unaffected. DelAGTG exhibited
increased catalytic efficiency for both substrates in comparison to wild-type, and
Q548X had only a slight increase in catalytic efficiency for succinyl-CoA. While
wild-type hALAS2 exhibited a sharp decrease in activity as the temperature
increased from 45°C to 55°C, the decrease in activity for the variants was less
abrupt and low levels of activity persisted up to 70°C. The purified XLEPP
variants are more stable at temperatures above 55°C, indicating that the variants
also have increased stability independent of interaction with SCS and resistance
to proteolysis. These results led us to examine the structures of purified wild-type
hALAS2 and the XLEPP variants.
The far-UV CD spectra for hALAS2 and the variants are dominated by αhelical structure, and are similar among the variants. However, upon addition of
succinyl-CoA, the XLEPP variants exhibit a change in secondary structure that is
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not evident with the wild-type enzyme. These CD spectra imply the possibility
that a structural change that occurs upon binding of succinyl-CoA could be the
reason behind the increased affinities of the XLEPP variants for succinyl-CoA.
Each variant has a distinct near-UV CD spectrum that differs in intensity and
shape from the wild-type enzyme, indicating that the positioning of the aromatic
amino acids is altered in the XLEPP variants. The CD signals in the visible
spectral region are excellent indicators of the integrity of the PLP cofactor-binding
site (5) because, as with other PLP-dependent enzymes (6,7), absorption
maxima at 330 and 420 nm are characteristic of different ionization states of the
internal aldimine bond between the PLP and the ALAS, corresponding to the
unprotonated and protonated forms, respectively (2,8). The binding of delAGTG
and Q548X to PLP display slightly higher intensity bands between 420-430 nm,
but exhibit large bands around 330 nm that are not evident in wild-type or delAT
CD spectra. PLP appears to bind these variants more tightly, and specifically in
both ionization states. Upon addition of succinyl-CoA, the band associated with
the unprotonated internal aldimine for delAGTG and Q548X shifts to the right to
become a broader band from 340-400 nm, indicating a change in the chirality of
PLP in the active site when succinyl-CoA is bound. These studies are the first
structural studies of the XLEPP variants of hALAS2 and they offer a new
perspective to what is known about the molecular mechanism behind XLEPP.
We provide evidence that XLEPP can be modeled in cell culture, and this model
may aid in testing for direct action of potential therapeutics on hALAS2. We also
found that the XLEPP variants are more thermostable, undergo distinct
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conformational changes upon the addition of substrate, and differ in tertiary
structure and PLP binding.
Using our developed cell culture model of XLEPP and purified
recombinant proteins, we then explored the effects of INH, focusing on
elucidating the mechanisms of INH-induced anemia and evaluating potential for
XLEPP drug therapy. Our studies using mammalian cell cultures indicate that
INH decreases PPIX accumulation in HeLa cells overexpressing hALAS2, and
demonstrate that INH is effective in reducing hALAS2 activity ex vivo. While
pyridoxine did not lessen the effect of INH on PPIX levels, addition of either PLP
or PMP completely reversed the effects of INH. The results of these initial
experiments might be interpreted by using the known PLP-dependent
mechanisms of hALAS2 inhibition by INH, in which INH inhibits pyridoxal kinase
(9,10), the enzyme that produces PLP, and also reacts with PLP to form
pyridoxal isonicotinoyl hydrazones (11,12), but do not rule out the possibility of
direct inhibition of hALAS2 by INH. We next used purified hALAS2 to test
whether INH could directly inhibit hALAS2, and found that INH inhibits purified
hALAS2 regardless of the presence of excess PLP. Excess PLP did, however,
affect the apparent Ki values for INH, indicating that a small percentage of the
INH might have reacted with PLP to form pyridoxal-hydrazones (12), thus
reducing the amount of INH available to inhibit hALAS2. However, 100 M INH
caused nearly 100% activity loss regardless of the concentration of PLP,
suggesting a PLP-independent mechanism of hALAS2 inhibition by INH. We
subsequently found that INH is not a competitive inhibitor for either the glycine or
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succinyl-CoA substrates, as it decreases the Vmax and increases the Km values
for glycine, and decreases the Vmax for succinyl-CoA. These data suggest that
INH binds to an alternate site that is distinct from the glycine-binding site, and
decreases the affinity of hALAS2 for glycine. Additionally, by evaluating the
inhibitory effects of pyrazinamide and 1,1-dimethylhydrazine, we concluded that
both the hydrazine moiety and the linkage of the hydrazine moiety on the pyridine
ring of INH are crucial for complete inhibition of hALAS2.
Given that INH does not compete with the substrates, one possibility is
that binding of INH stabilizes the closed conformation of hALAS2. INH could bind
both the hALAS2 holoenzyme and glycine-bound hALAS2, which is consistent
with partial inhibition of the enzyme. To better resolve the mechanism of
inhibition, we examined the possibility of structural changes associated with
binding of INH to hALAS2. The changes in fluorescence of the aromatic residues
of hALAS2, as seen in CD spectra, indicate that INH elicits a protein
conformational change that renders the enzyme either less active or inactive. CD
spectroscopy also revealed a concentration-dependent decrease in the mean
residue molar ellipticity band between 420-440 nm, indicating that INH disrupts
the hALAS2-PLP bond, apparently yielding an enzyme devoid of the Schiff base
linkage. Decreased PLP binding of ALAS2 has been noted previously with
mouse ALAS2 when serine 254 was mutated to an alanine residue (13). This
active site mutation causes a change in the microenvironment of the PLP
cofactor and disrupts the binding of succinyl-CoA (13). Our data suggest that INH
is an inhibitor of hALAS2 that affects the functionality of the PLP cofactor. We
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propose a mechanism by which addition of INH to hALAS2 results in structural
rearrangement of the protein and disruption in the hALAS2-PLP linkage, thus
inhibiting hALAS2 activity. To determine the position and location at which INH
binds to hALAS2, further studies including x-ray crystallization of hALAS2 with
INH are warranted. These data provide support for using INH to treat cutaneous
porphyrias, especially for XLEPP, where hALAS2 is overly active. The direct
effect of INH on hALAS2 activity should also be considered when treating
tuberculosis patients who have developed sideroblastic anemia.
In conclusion, this body of work explores mutations in ALAS2 that cause
increased PPIX from two different perspectives. Firstly, we investigated
mutations to be utilized as tools for developing ALAS-PDT, and found that
mutation of the HRMs, in combination with the R433K mutation, results in
significant cellular PPIX accumulation and up to 90% cell death upon light
treatment. Secondly, we studied mutations in hALAS2 associated with the
disease XLEPP, and elucidated structural changes that help to explain how the
C-terminal mutations result in changes in catalytic activity of hALAS2, which in
turn produce the symptoms of XLEPP. Furthermore, we presented INH as an
inhibitor of hALAS2 and a promising therapy for XLEPP patients.
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